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Abstract
Renal Cell Carcinoma (RCC) is the most common and fatal type of kidney cancer. Over 30% of
patients that are diagnosed with RCC exhibit metastases. Almost 88% of patients with distant
metastases succumb to the disease within 5 years of diagnosis. Kidney Injury Molecule-1 (KIM1) is a cell surface glycoprotein that is not expressed in a healthy kidney but becomes highly
expressed on proximal tubular epithelial cells (PTECs) following injury. Data from the Cancer
Genome Atlas (TCGA) reveals that >90% of RCC tumours express KIM-1 mRNA and that
higher expression levels correlate with increased overall survival rates of patients. The
pathophysiological role of KIM-1 in RCC is not well understood. Using human (786-O) and
murine (RENCA) models, we recently uncovered that KIM-1 may inhibit the metastatic
properties (invasion and extravasation) of RCC cells using in vivo and in vitro systems. The aim
of this thesis work was to elucidate the mechanism by which KIM-1 regulates RCC tumour
progression using syngeneic and pre-clinical orthotopic RENCA models.
Transcriptomic analysis of RENCA cells lacking or overexpressing KIM-1, and The Cancer
Genome Atlas (TCGA), revealed significant upregulation of genes involved in extracellular
matrix (ECM) interactions in association with KIM-1 expression. In vivo, subcutaneous
implantation of RENCA tumours resulted in the development of thick, collagen dense, stromal
capsules surrounding the tumours. This was observed in both immune-competent and immunedeficient mice. In a pre-clinical (orthotopic) model, KIM-1 expression inhibits primary RENCA
tumour growth within the kidneys. Lastly, significant phenotypic differences in primary tumour
growth, and histology were observed in between subcutaneous and orthotopic implantation of
RENCA tumours.

Lay Summary
Kidney cancer comprises almost 4% of all adult malignancies and is the 8th most common type
of cancer in humans. Renal Cell Carcinoma (RCC) is the most common and lethal type of kidney
cancers. RCC is most lethal when it spreads to distant sites because it is resistant to many forms
of anti-cancer therapy including chemo-, radio- and even modern immunotherapies. Over one
third of patients have cancer that has spread at the time of diagnosis. Kidney Injury Molecule-1
(KIM-1) is a normal protein that is found in injured human kidneys and is aberrantly present in
over 90% of RCC tumour samples obtained from cancer patients. Patients whose tumours have
high amounts of KIM-1 seem to survive longer (due to cancer spread likely) but the reason for
this is not known. The objective of my thesis was to determine how KIM-1 may protect patents
with RCC from dying using genetic techniques and animal models of kidney cancer.
My work suggests that the role of KIM-1 in RCC greatly depends on the tumour model used.
Overall, KIM-1 may protect patients with RCC by slowing the growth of tumours, and
potentially, the spread of cancer cells to distant sites from the primary tumour. Our genetic
studies suggest that KIM-1 may achieve this by altering the genes produced by the kidney
tumours to produce a thick, collagen dense “capsule” around them. Further studies of these
“protective” genes may help us to develop treatments for patients with RCC and potentially other
cancers.
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Chapter 1
1. Introduction
1.1 Cancer
Cancer is defined as a group of diseases that is caused by abnormal cells undergoing
uncontrolled proliferation within any part of the human body that has the potential to invade
nearby tissues or spread to distant tissues. Tumours consist of a (solid) collection of cells which
can be benign or malignant. Malignant tumours are made up of cancerous cells which can cause
death by infiltrating or destroying normal (local or distant) tissues (World Health Organization,
2018). Globally, cancer is the second leading cause of death – 1 in 6 deaths are caused by cancer
(World Health Organization, 2018). According to the American Cancer Society in 2020,
1,806,590 new cancer cases were reported, with a total of 606,520 deaths (Siegel, Miller and
Jemal, 2020). The Canadian Cancer Society, in 2019, estimated that nearly 1 in 2 Canadians will
be diagnosed with cancer within their lifetime. In 2019 alone, it was estimated that 220, 400 new
cases of cancer were expected to be diagnosed in Canada. Out of these expected cases, males
have a slightly higher incident rate than females, with numbers at 113,000 cases vs 107,400 cases
respectively. The risk of developing cancer in Canada has increased significantly with our aging
population (Canadian Cancer Statistics Advisory Committee, 2019). Genetic alterations to
cellular DNA and/or environmental effects are believed to be central to the development of many
types of cancer. Unhealthy diets, physical inactivity, drug and alcohol abuse are all
environmental factors that have been linked to an increased incidence of cancer worldwide.
Various chronic infections can increase the risks of cancer development. For example, chronic
infections such as with Helicobacter pylori and human papillomavirus (HPV) can result in the
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development of pyloric and cervical cancer, respectively. One of the most common causes of
death from cancer is the process of metastasis (World Health Organization, 2018). Metastasis is
the process by which cells within a primary tumour break away from their originating boundary
of growth, travel and inhabit local (neighboring) or distant tissues, resulting in the growth of a
secondary tumour.
Hanahan and Weinberg famously proposed the six characteristics needed for cancer progression.
These have been coined the hallmarks of cancer (Hanahan and Coussens, 2012). The six
fundamental hallmarks of cancer include: sustained cell proliferation signaling, evading tumour
and/or growth suppressors (e.g., immune system), invasion and metastasis, immortal replication,
induction of angiogenesis and lastly resisting cell death. All of the listed hallmarks are key
characteristics present in the vast majority of human cancers. These hallmark properties allow
cancers to promote site specific inflammation, genetic instability leading to additional mutations,
and evasion of immune destruction. These processes also allow for the cancerous cells to recruit
non-neoplastic cells to the site of malignancy (e.g., macrophages), in order to benefit the cancer's
progression. Critically investigating these mechanisms for specific cancers, allows us to have a
better understanding of pathogenesis of that cancer and, to in turn, create higher efficacy
treatments.
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Figure 1. Hallmarks of Cancer
The six original hallmarks of cancer (Hanahan and Weinberg) along with newly found
mechanisms that contribute to progression and metastasis (adapted with permission from
Hanahan and Weinberg, 2011). Diagram including potential cancer therapeutics that can help
combat the above mechanisms to benefit cancer treatment.

1.2 Renal Cell Carcinoma
Kidney cancer has been identified as the 8th most common form of cancer, causing 179,386
deaths globally in 2020 alone (Globocan, 2020). Renal cell carcinoma (RCC) is the most
common form of kidney cancer, compromising up to 85%-90% of all cases (Chang et al., 2016).
RCC has the highest mortality rate out of all genital and urinary cancers. The Canadian Cancer
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Statistics 2019 found from the approximate 100,000 new cases of cancer, renal and pelvic
cancers have affected 4.2% and 2.3% of males and females, respectively (Canadian Cancer
Statistics Advisory Committee, 2019). RCC is characterized as being a highly immunogenic
cancer – where RCC tumours are recognized as foreign and elicit a strong adaptive immune
response against it. By definition, the occurrence of RCC implies that these tumours evade the
host’s immune system. The survival rates vary greatly depending on the progression and
presence of metastasis. If RCC is detected early while still being localized to the affected kidney
(contained within the Gerota’s fascia), surgical resection can be curative, although recurrence
occurs in 20%-40% of those who have undergone surgical management (Chin et al., 2006).
Patients with distant metastases (metastatic RCC) have significantly reduced survival rates
(American Cancer Society, 2016). Specifically, approximately 12% of patients with advanced
disease die within 5 years of initial diagnoses (Choueiri and Motzer, 2017).

1.2.1 RCC Subtypes and Histological Properties
Histological analysis of RCC tumours is extremely important in determining patient prognosis as
it aids not only in the diagnosis but also provides information about the histopathological type of
RCC. Nephrectomy is used to make a tissue diagnosis before embarking on treatment. On rare
occasions, percutaneous biopsy of small renal masses is undertaken if there is a high degree of
suspicion of a metastatic lesion to the kidney from another type of cancer (Sahni and Silverman,
2009).
RCC is classified using histology into subtypes; Clear Cell Carcinoma (ccRCC) compromising
~75%, Papillary RCC (pRCC) compromising ~10%, Chromophobe RCC compromising ~5%,
and lastly Collecting Ducts and Medullary RCC compromising each ~1% (Cairns, 2011; Li and
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Kaelin, 2011). Up to 5% of RCC remain unclassified. The cellular morphology of ccRCC is
characterized by cells with a lipid-rich cytoplasm. For pRCC, subtype 1 consists of spindleshaped cells surrounding a basal membrane, and subtype 2 consists of spindle-shaped cells with
visually prominent nuclei and an eosinophilic granular cytoplasmic space. Collecting Duct RCC
histologically will present abnormal cells infiltrating the walls of the collecting ducts, causing a
significant desmoplastic reaction. Lastly, Medullary RCC represents neoplasms localized to the
distal nephron, characterized by hyperchromatic nuclei (Muglia and Prando, 2015).

1.2.2 Staging
Staging studies are crucial to developing a therapeutic plan for affected patients. A variety of
imaging modalities are used to determine the size of the tumour as well as the extent of local and
regional involvement. The most widely used is the (The American Joint Committee on Cancer
(AJCC), 2017) Tumour, Node, Metastasis (TNM) (anatomic) staging system and it is used for
staging all histological variants of RCC. The anatomic extent of disease is the most consistent
predictor of prognosis in patients with RCC. In early stages – classified as either stage I or II tumours can be any size (<7cm stage I, >7cm stage II) in diameter but are localized to the
affected kidney only. Stage III is characterized by tumours of an undefined size within the
affected kidney and metastasis to regional lymph nodes and/or into the major veins or
perinephric tissues (but not beyond the Gerota’s fascia of the kidney or into the ipsilateral
adrenal gland) (Reznek, 2004). Lastly, stage IV is characterized by tumours that have spread
beyond the Gerota’s fascia to nearby tissues including the ipsilateral adrenal gland (Sandock,
Seftel and Resnick, 1997). When metastatic disease is suspected at initial presentation,
pathologic confirmation is obtained prior to starting therapy. The most common sites of
metastasis are the lungs (29-54%), bones (16-31%), liver (8-30%), renal fossa and brain (2-10%)
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(Shao et al., 2019). Although approximately 65% of tumours are limited to the kidney (Stage IIII) at initial diagnosis, over 20% of these patients will experience a relapse after receiving
definitive treatment (Shao et al., 2019).

1.2.3 Risk Factors and Causes
A number of established risk factors exist for the development of RCC and include both genetic
and environmental factors. A number of hereditary kidney cancer syndromes have been
described including autosomal dominant polycystic kidney disease, Tuberous Sclerosis Complex
and Von Hippel-Lindau disease (Gnarra et al., 1994; Keith et al., 1994; Yang et al., 2014). The
most common genetic alteration found in patients with sporadic RCC is the mutation of the von
Hippel-Lindau tumour suppressor gene, also known as the VHL gene. Similar to many genes,
VHL is co-dominantly expressed. In familial RCC, gene alterations of one inherited allele causes
patients to exhibit VHL disease predisposing them for RCC tumour growth. In sporadic RCC,
both alleles of the VHL gene are functional at birth, yet bi-allelic gene alterations occur
postnatally causing the spontaneous development of RCC (Ma et al., 2001).
The VHL gene is located on chromosome 3p region and encodes for the VHL protein. VHL
protein acts as a tumour suppressor gene by regulating cellular division and preventing increased
proliferation (Gnarra et al., 1994). The VHL protein is mostly commonly known to form a stable
protein complex with elongin C and B, as well as proteins Cul-2 and RBX-1 (Pause et al., 1997).
This VHL protein complex functions as a ubiquitin-protein ligase, that has many downstream
effector targets. In normoxic, healthy conditions - where the VHL gene is unaltered – the VHL
protein complex is able bind to the hydroxylated form of hypoxia inducible factor 1-alpha (HIF1α) or hypoxia inducible factor 2-alpha (HIF-2α) and target the subunit for degradation via
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ubiquitination. Under conditions of hypoxia, HIF-2α escapes ubiquitination by VHL as it is not
hydroxylated by oxygen-dependent prolyl hydroxylases (Groulx and Lee, 2002). Under
conditions where the VHL gene is altered and non-functional, the VHL protein complex is
unable to bind to hydroxylated HIF-1α and thus unable to target the complex for destruction.
Due to this, HIF-1α becomes continuously expressed on cells leading to the enhancement of
downstream HIF transcription factors, also acting as a positive feedback loop. Overall, increased
HIF transcripts result in cellular dysregulation. For example, HIF-2α enhancement mimics
hypoxic cellular conditions activating apoptotic and glycolytic pathways, while increased HIF-2α
enhances angiogenesis and cell proliferation. Inactivation of VHL results in upregulation of
VEGF, which results in increased metabolism and angiogenesis (Verine et al., 2010). Overall,
the HIF-2α transcripts together with the malignant tumour microenvironment (TME) resulting
from excess VEGF drive the development and progression of RCC (Rechsteiner et al., 2011).

1.2.4 Treatments for RCC
1.2.4.1 Surgery
As of today, there is no therapy for RCC that is guaranteed to be curative, but some patients have
experienced complete and permanent remission. The field has seen many advancements in
therapeutics owing to recent breakthroughs in cancer immunology. Treatments options for RCC
range from surgical resection to non-targeted (older) drugs, to molecular targeted therapies, to
novel immunotherapies and various combinations of these which are currently being tested in
clinical trials. The most successful and tried form of treatment for localized RCC (stage I-III) is
surgical resection, either through partial or radical nephrectomy. This consists of the removal of
only a portion of the kidney containing the tumour, removal of one affected kidney, or removal
of the affected kidney along with nearby lymph nodes and adrenal gland, respectively (National
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Cancer Institute, 2020). Unfortunately, surgery has major limitations as a primary treatment.
Nephrectomy is indicated for patients with tumours contained within the kidney’s Gerota’s fascia
(stages I-III) (Reznek, 2004). Radical or partial nephrectomy have been found to improve
patients' 5-year survival rate. However, in patients that present with metastatic RCC, surgery
alone is not a feasible form of treatment, and is only used in order to reduce painful symptoms or
as cytoreductive treatment in combination with systemic therapy (De Vivar Chevez, Finke and
Bukowski, 2014).

1.2.4.2 Targeted Therapies
Decades of research into the pathogenesis of clear cell RCC (the most common subtype),
including the discovery of the roles of HIF-2 and VEGF, have led to the development of a
myriad of molecular targeted therapies for patients with RCC (Cho et al., 2016; Choueiri and
Kaelin, 2020). Instead of enhancing mechanics of the immune system to combat disease,
molecular targeted therapies attack or inhibit mechanisms that assist directly in cancers
progression (see hallmarks of cancer above). These include inhibiting processes such as
angiogenesis and increased proliferation. The knowledge of the crucial role of mammalian target
of rapamycin (mTOR) and vascular endothelial growth factor (VEGF) (or its receptor) in the
progression and metastases of RCC have greatly improved treatments of metastatic RCC (Heng,
Kollmannsberger and Chi, 2010). mTOR is a highly conserved protein kinase that regulates cell
proliferation, apoptosis, along with various signaling biological pathways within the body.
mTOR is a downstream effector of the PI3-K/Akt/mTOR pathway. This signaling pathway is
activated in RCC tumours, playing a significant role in cell proliferation, tumour metabolism,
and immune cell differentiation also creating a positive feedback loop. Initiating the PI3K/Akt/mTOR pathway is caused by the extracellular binding of growth factors which initiate
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activation of tyrosine kinase receptors (Porta, Paglino and Mosca, 2014). This interaction
mediates intracellular PI3-K to phosphorylate PIP2 into PIP3. PIP3 then binds to the activated
PDK1/2 complex which downstream binds to Akt at its PH domain, allowing activation through
phosphorylation (Battelli and Cho, 2011). When Akt is in its activated state, it has the ability to
inhibit the tumour suppressor complex TSC1/TCS2. Downstream, this complex inhibits Rheb
GTPase – a crucial player in the inhibition of mTOR signaling pathway in cancer. With
inhibition of the tumour suppressor TSC1/TCS2 complex and Rheb, mTOR signaling allows for
anabolic proliferation and dysregulation of cellular functions (Huang and Manning, 2008).
Allosteric inhibitors of mTOR such as temisirolimus and everolimus, have shown significant
anti-tumour effects in patients with advanced staged RCC. Combination strategies also increase
efficacy and overall patient response.
Another targeted therapy commonly used in RCC treatment is anti-VEGF. VEGF is identified as
an important mediator in the development and progression of RCC, as it greatly impacts tumour
vascularity and thus metabolism (Stitzlein, Rao and Dudley, 2019). Specifically, HIF
transcription factors target genes such as VEGF, PDGF, IGF, and TGF- which directly
implicate alterations in angiogenesis, glucose transport, apoptosis, cell signaling, and pH
regulation. Various multi-kinase inhibitors such as sorafenib, are able to inhibit VEGF, PDGF, cKit receptor tyrosine kinases and show positive results in reduction of disease in metastatic RCC
patients, with feasible toxicity (Larkin and Eisen, 2006).

1.2.4.3 Immunotherapies
Other forms of treatment involve the use of immunotherapies. Immunotherapy is a form of
treatment which uses the patient’s own immune system to target and potentially destroy the
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cancer. Immunotherapies are an integrated form of therapy for RCC yet have shown positive
results due to RCCs immunogenic nature. In the early 1990’s, Interleukin-2 (IL-2) and IFNγ
were the first cytokine specific treatments used to treat metastatic RCC. These two cytokines
were chosen because: IL-2 promotes T-cell activation and effector function; and IFNγ triggers
activation of T-cells, enhances antigen presentation by antigen-presenting cells and promotes
activation of macrophages (Tau and Rotherman, 2001). In 1992 the FDA approved high-dose IL2 as a treatment for advanced RCC (Rosenberg, 2007). Patients experienced overall response
rates of up to 25%, although IL-2 was not well-tolerated amongst patients due to its toxicity at
high doses. Later on, IFNγ was tested as a monotherapy for metastatic RCC patients. Clinical
trials began using low-to-moderate doses of IFNγ – as they were deemed more biologically
effective in previous in vivo experiments rather than higher doses. Early-stage clinical trials
consisted of doses at 100g/patient administered once per week, resulting in promising outcomes
where the total response rate was 30%, and well tolerated by patients (Aulitzky et al., 1989). In
trials with patients with later stage disease, there was found to be no significant difference
between both response and survival rates when comparing placebo to treatment. Hence, IFNγ as
a monotherapy was not further investigated for RCC treatment. With these promising results,
combination therapy of IL-2 and IFNγ began to be administered to RCC patients. Although these
results were positive, only a small fraction of patients responded to the therapy, albeit
incompletely (Escudier et al., 1993).
More recently, the field has seen the emergence of ground-breaking immunotherapies that target
T cell checkpoints (e.g. programmed cell death ligand-1 (PDL-1) and programmed cell death-1
(PD-1) and/or CD80/CD86 and cytotoxic lymphocyte antigen 4 (CTLA-4)). The agents are
primarily monoclonal antibodies that block inhibitory signaling by the ligand-receptors pairs.
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PD-1 is a receptor expressed on antigen presenting cells of the immune system, and when bound
by its ligand PDL-1 – commonly found on antigen presenting cells and some cancer cells
(Weinstock and McDermott, 2015) – suppresses T cell activation, allowing the tumour to escape
immune destruction primarily through the exhaustion of cytotoxic CD8+ T cells (Lu et al., 2019).
These immunotherapies have shown favorable results in in clinical trials when delivered as a
monotherapy or in combination with other immunotherapies (anti-CTL-4) (Motzer et al., 2018).
Therapy was associated with an increase in intratumoural T-cell tracking, reduced
immunosuppressive cytokines and T-regulatory cells, as well as an increase in anti-angiogenic
properties (Weinstock and McDermott, 2015). In the process of T cell activation/priming, two
positive activating signals must take place between T cell and antigen presenting cells (APCs) to
allow for the success of T-cell priming. Stimulatory signal consists of the T-Cell Receptor (TCR)
to the Major Histocompatibility Complex (MHC) presenting the unknown peptide, along with
CD28 engagement on T-cells to CD80/CD86 on the APC. During times of autoreactivity
(Boehncke and Brembilla, 2019), CTLA-4 on T-cells will bind to CD80/CD86 on the surface of
APCs sending a inhibitory signal, rendering the T cell to become inactive (Buchbinder and
Desai, 2016). CTLA-4 - an inhibitory molecule binds to CD80/CD86 (B7-1/B7-2) with much
greater affinity than CD28 on T cells, and when engaged delivers an inhibitory signal to
activated T cells (Pardoll, 2012). In cancer, blocking the inhibitory signal between CTLA-4 and
CD80/CD86 has been found to enhance both priming and activation of T cells and various
immune cells (Tang et al., 2018). Thus, using monoclonal agonist antibody anti-CTLA-4
(Ipilimumab) as an immunotherapy in RCC, has been shown to increase T cell effector functions
resulting in enhanced anti-tumour immunity (Seidel, Otsuka and Kabashima, 2018).
Combination therapy with both anti-PD1 and anti-CTLA-4 antibodies was shown to have
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synergistic effects on anti-tumour immunity, being able to increase overall response rates against
malignancies (Motzer et al., 2018). Although this therapy has been shown to cause progressionfree outcomes with increased overall survival, there is still a major limitation of patient-patient
variation in response (Cairns, 2011). Also, the overall response rates have been low (Weinstock
and McDermott, 2015).

1.2.5 Patient Immune Profile or Immune Microenvironment
To enhance potential treatments, patient profiles have been examined to comprehend the
immunological mechanisms throughout the clinical stages of RCC. Many clinical studies have
evaluated patient serum for cytokine levels, indicative of the immune phenotype and tumour
microenvironment present. A recent clinical study aimed to find differences in tumour-associated
interleukins (IL) and cytokines from collected metastatic RCC patients treated with IL-2
immunotherapy and compare the results of serum from healthy donors. This study aimed to find
differences in immunomodulatory cytokines such as IL-10, IL-6, IL-12, IL-8, and IL1β, as well
as tumour necrosis factor-alpha (TNFα). Results found higher levels of cytokines that implement
an immunosuppressive effect; increased IL-8, IL-6, and c-reactive protein. Patients found to have
an immunosuppressive cytokine profile correlated directly with an overall reduced survival rate
(Guida et al., 2007).

1.2.6 The Tumour Microenvironment (TME)
The tumour microenvironment (TME) is made up of cancer cells, stromal tissue, and
surrounding extracellular matrix. The immune system plays a fundamental role in shaping the
TME. Intense study of the complex interactions between cancer cells and the host immune
response has led to novel therapies that serve to block tumour progression. This interaction often
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creates an environment that promotes tumour progression throughout all stages of malignancy. In
immunogenic cancers, similar to RCC, the TME contains a vast variety of immune cells such as
CD8+ T cells, γδ T cells, along with fibroblasts, and endothelial cells (Hanahan and Coussens,
2012). The types of immune cells (e.g. T cells, innate lymphoid cells, macrophages etc.) within
the TME are believed to be dependent on cell-cell communications between the RCC cells, the
extracellular matrix and immune cells. Various studies investigating the transcriptomic profile of
human RCC tumours have allowed for a clearer understanding of the components within RCC
TME. This information has helped us to understand why RCC is able to evade immune
destruction, despite being a highly immunogenic cancer. Immune signatures that are commonly
observed in RCC are the expression of tumour promoting checkpoint inhibitors PD1, PDL1, and
CTLA-4. Histopathologic and transcriptomic analysis of RCC tumours has identified three
distinct immune profiles : 1) T cell enriched tumours that are infiltrated with an abundant
quantity of T-Lymphocytes; 2) Non-infiltrated tumours that have a scarcity of infiltrating
immune cells, and 3) Heterogenous tumours that are composed of diverse amounts of immune
cells alongside the malignant cells. RCC tumours follow the phenotype of 1) or 3) – being a
cancer with one of the highest T cell infiltrates and/or having tumours with heterogenous
immune profile containing diverse types immune cells. Despite this immunogenic feature of
RCC tumours – many patients succumb to the disease. A majority of RCC patients present with a
heterogenous immune profile – although seemingly beneficial to patients - outcomes of this
TME result in the poorest survival. The abundance of antigen presenting machinery also does not
have clear correlations with tumour progression. Thus, analyzing specific immune cell effector
functions along with their abundance can better help understand why these highly infiltrated
tumours are able to evade immune destruction immunogenic. RCC tumour immune infiltrates
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contain vast levels of mainly CD8+ T cells, neutrophils, macrophages, and plasmacytoid
Dendritic Cells (pDC). Higher frequencies of cytotoxic cells such as CD8+ T cells within the
TME is a characteristic that would seem to be extremely beneficial to patients, yet with RCC,
high correlations of CD8+ T cells alone do not correlate to increased survival. Instead, a higher
ratio between cytotoxic and immune regulatory cells improve survival; specifically, the balance
between CD8+ T cells and T regulatory cells (Tregs) is shifted to CD8+ T cells. Tregs are a
specialized immune cell able to suppress T cell proliferation and activity; known to inhibit
autoimmunity, yet in cancer are able to suppress anti-tumour T cell immunity (Romano et al.,
2019). Heterogenous RCC tumours have significant changes when compared to T cell enriched
profiles, suggesting that the T cell enriched tumours have distinct gene alterations that cause this
unique immune profile (Şenbabaoğlu et al., 2016). The enhancement of the T cell enrichment in
RCC tumours could be due to genomic alterations that generate neoantigens or make existing
antigens more immunogenic (Germano et al., 2017) .
Another common phenotype observed in the TME of multiple cancer types is the abundance of
extracellular matrix (ECM). ECM is a crucial component of the TME – able to influence tumour
cell activity and biosynthesis (Xu et al., 2019). A major component of the ECM are the collagens
present (Nissen, Karsdal and Willumsen, 2019). Several mutated genes influence the interaction
between cancer cells and the elements compromising the ECM, which can contribute to
increased production of collagen (Xu et al., 2019). Collagen activity such as degradation and redeposition within a tumour can affect several processes in cancer progression such as infiltration,
invasion, migration, and angiogenesis. The role of collagen in cancer has been found to have a
paradoxical effect by both promoting and inhibiting tumour progression throughout cancer
development (Fang et al., 2014). In vitro studies have shown that collagen deposition is able to
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inhibit lymphocyte locomotion in both human melanoma and RCC (Applegate, Balch and Pellis,
1990). In human lung tumours, collagen deposition is directly related to decreased intratumoural
cytotoxic CD8+ T cells – specifically, collagen is found to induce CD8+ T cell exhaustion
through collagen receptor interaction of LAIR1. More importantly, this study also revealed that
increased collagen deposition is able to promote immune checkpoint blockade PD-1/PDL-1
resistance (Peng et al., 2020). On the other hand, hypermethylation thus inactivation of specific
collagen genes such as collagen type 1  2 (COL1A2), increase invasive capabilities of human
bladder cancer (Mori et al., 2009). Specifically, the role of collagen on RCC tumour progression
is not fully understood. Using both TCGA database and histological analysis of ccRCC human
tumours have revealed that collagen type 23   (COL) correlates with larger tumour sizes
and decreased overall survival, respectively (Xu et al., 2017). Tumour tissue bank analysis has
also implicated collagen type 6   (COL6A1) to be a predictive marker for overall survival of
ccRCC patients (Wan et al., 2015). Although RCC immune profiles and TME associated genes
of interest (COL23A1 and COL6A1) have been classified, the mechanisms that occur to
differentiate these microenvironments are not well understood. In order to combat this disease,
we must elucidate the cellular mechanisms that cultivate a malignant TME in RCC tumours.

1.2.7 Murine Models for Renal Cell Carcinoma
A variety of murine models are used to study the in vivo progression and metastasis of RCC.
Murine models of RCC have been found to accurately reflect human disease and can be used
widely in experiments investigating primary and secondary tumour progression, as well as
therapeutic treatment evaluation (Murphy and Hrushesky, 1973). Three types of animal models
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that are widely used in the in vivo research of RCC are syngeneic models, xenograft models, and
genetically engineering mouse models (GEM).

1.2.7.1 Syngeneic & Genetically Engineered Mouse (GEM) Models of RCC
The two major types of cancer models are the spontaneous and transplanted tumour models.
Recent breakthrough in our understanding of genetic defects in clear cell RCC has led to the
development of new spontaneous models of murine RCC (Harlander et al., 2017). However, the
vast majority of RCC research has relied on transplant models in mice (Sobczuk et al., 2020).
Syngeneic models are the transplantation of a cancer cell line that has the same genetic
background as the host (mouse). One of the most widely used murine syngeneic models of RCC
is the Renca model where the murine RCC cell line is transplanted into BALB/c Wild-type mice.
This mouse model is syngeneic because Renca is a murine RCC cell line that was derived from a
BALB/c mouse that spontaneously developed a renal malignancy (Murphy and Hrushesky,
1973). There are many advantages to using the syngeneic mouse model – they are more
economical and simplistic. Syngeneic models have been crucial to developing and studying the
mechanism of novel immunotherapeutics for RCC, including immune check-point inhibitors. For
instance, this model allows for the investigation of how the immune system interacts with the
cancer – this has permitted investigations of tumour immune profiling as well as tumour
microenvironmental changes that occur in RCC. Another commonly used murine model is
genetically engineered mouse (GEM) models. The GEM models are created by introducing
genetic alterations of possible genes of interest thought to be involved in the progression of
disease. This can include one or more genes that can be deleted, mutated, or overexpressed
(Sobczuk et al., 2020).
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1.2.7.2 Xenografts
Another tumour transplant mouse model that is commonly used is the xenograft model. Here
human derived cell lines or tissues are implanted into either humanized or immune deficient
mice. These models can be differentiated in two forms of experimental use: xenografts using
conventional cell lines, or xenografts using patient derived specimens. Commonly used mice for
xenograft implantation are Rag1-/- deficient mice, severely compromised immunodeficient
(SCID) mice, or nude mice (lack thymi and hence T cells). Each murine model has an
insufficient adaptive immune response, allowing for neo-antigens of the human derived
transplanted cell lines to pass immune surveillance and create a tumour (Richmond and Yingjun,
2008). Xenografts are more clinically relevant because they utilize human cells, yet are limiting
due to genetics and histology poorly reflecting human cancers (Becher and Holland, 2006).

1.2.7.3 Limitations of Murine Models
Each tumour model has its advantages and disadvantages, but as a whole, they have aided
scientists to better understand the biology of RCC. Some are more clinically relevant and better
suited for testing potential therapies. Unfortunately, a vast majority of kidney cancer cell lines
are not compatible with syngeneic and GEM murine models. Many syngeneic models are used
within rodents such as mice and rats, yet poorly reflect the development and progression of
human cancers. The mouse models that correlate best with clinical findings in patients are the
xenograft and GEM models as they mimic the genetic alterations and/or histological properties
of human RCC (Sobczuk et al., 2020). Although, GEM models often poorly predict human
tumour response to therapy (Richmond and Yingjun, 2008). Another major pitfall of the
syngeneic mouse model is that the stromal component of TME observed within the tumour

18
model is made of mouse cells. Due to this, tumour microenvironmental studies may not
accurately represent that of the human RCC TME.

1.2.7.4 Subcutaneous vs. Orthotopic (pre-clinical) Models of RCC
Syngeneic, xenograft, and GEM models can all undergo cancer cell line injections using
different methods of implantation. Subcutaneous delivery is the most common form of cancer
cell line implantation – it is the process of injecting cancer cells in the space underneath the skin
and above the muscle, commonly within the flanks of mice. Although this model allows for the
easy establishment and monitoring of tumours over the skin using calipers, this mode of
implantation does not reflect the natural microenvironment of human RCC. A more clinically
relevant model of RCC is the orthotopic model – here RCC cell lines are implanted into the
kidney (where RCC originates in the human body). Orthotopic injections can be performed with
syngeneic, xenograft, and GEM mouse models (Richmond and Yingjun, 2008). Orthotopic
implantations have been shown to mimic primary tumour progression, local invasion and
spontaneous metastases to distant organs such as the lymph nodes, lungs and liver as observed in
human RCC (Salup, Herberman and Wiltrout, 1985).

1.3 Kidney Injury Molecule-1
Kidney injury molecule-1 (KIM-1), also known as hepatitis A virus cellular receptor 1
(HAVCR1) or T cell immunoglobulin receptor mucin domain 1 (TIM-1) , is a cell-surface
receptor (Han et al., 2002). KIM-1 belongs to the TIM family of glycoproteins which are type-1
transmembrane proteins consisting of an extracellular immunoglobulin like IgV domain, a hyperglycosylated mucin domain, a transmembrane domain and an intracellular cytoplasmic domain.
KIM-1 is expressed on various human tissues and cell types including the kidney, liver, lung,

19
spleen, T cells and B cells– possessing multiple functions including its involvement in acute
kidney injury and repair, hepatitis A virus infection, T cell trafficking and autoimmunity
(Bonventre, 2009; Zheng et al., 2019). In the kidney, KIM-1 is not expressed during a healthy
state but is the most upregulated protein following acute kidney injury (Ichimura et al., 1998).
KIM-1 is specifically expressed on the apical surface of proximal tubule epithelial cells (PTECs)
immediately following kidney injury (Bonventre, 2008; Ajay et al., 2014). Interestingly, KIM-1
undergoes spontaneous and accelerated (with more injury) ectodomain shedding releasing the
cleaved or soluble KIM-1 into the lumen of the kidney, ultimately ending up in the blood and
urine of affected patients (Gandhi et al., 2014). This makes KIM-1 a sufficient clinical biomarker
for kidney injury in the urine and plasma of humans, mice, and rats (Sabbisetti et al., 2014).

1.3.1 Function of KIM-1 in the Kidney
The IgV portion of KIM-1 contains an ion-dependent ligand binding domain that forms an active
site for recognition of the membrane phospholipid, phosphatidylserine (PtdSer) (Santiago et al.,
2007) – “eat me” signal - that is expressed on the outer surface of early necrotic and apoptotic
cells. KIM-1 is a scavenger receptor that is able to recognize other “eat me” signals on apoptotic
cells such as oxidized low-density lipoproteins (LDL) (Ichimura et al., 2008). Thereby, KIM-1
enables PTECs to engulf apoptotic cells, promoting repair and regeneration of the renal tubules
following acute kidney injury (Yang et al., 2015; O. Z. Ismail et al., 2016). Binding of KIM-1 to
apoptotic cells triggers intracellular signaling via its cytosolic domain to inhibit NF-kB activation
and downregulate Toll-like receptor 4 expression (Yang et al., 2015). The clearance of necrotic
cells, which predominate after acute kidney injury, is also facilitated by KIM-1 expressing
PTECs, but this requires the opsonin, Apoptosis Inhibitor of Macrophages (AIM), which is
appears in the tubules through glomerular filtration of blood. Within the tubules, AIM opsonizes
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necrotic debris and cells, subsequently allowing KIM-1 to bind to AIM and engulf the debris via
KIM-1/PTEC mediated phagocytosis (Arai et al., 2016). This rapid clearance of dead cells
prevents excess inflammation build up and the release of danger associated molecular patterns
(DAMPs) from the apoptotic cells (Kobayashi et al., 2007).

1.3.2 KIM-1 in RCC
KIM-1 expression is elevated in approximately 80%-90% of human RCC patients, specifically
expressed in both clear cell RCC and papillary RCC – two of the most common forms of RCC
(Han et al., 2005; Lin et al., 2007). Both of these subtypes of RCC have allowed for the noninvasive surveillance and early detection of RCC development through detectable levels of
soluble/shed KIM-1 in patients plasma and urine (Han et al., 2002). Urinary KIM-1 is
significantly upregulated in RCC patients prior to surgical nephrectomy, and subsequently
reduced either with notable reduction or complete absence of urine KIM-1 post-nephrectomy
(Zhang et al., 2014). Recent studies have also shown that as early as 5 years before initial
diagnosis of RCC, KIM-1 is upregulated in the plasma of patients (Scelo et al., 2018).
The pathophysiological role of KIM-1 in human RCC is not well known. There have been
several studies that have proposed conflicting roles for KIM-1 in RCC. Research by Scelo and
Muller et al., 2018 found that increased plasma concentrations of KIM-1 were associated with
worse survival rates in RCC patients (Scelo et al., 2018). Another study by Cuadros et al., 2014,
studied intrinsic mechanisms involved in the progression of RCC. Specifically, this study
analyzed the human RCC cell line, 769-P where KIM-1 is basally overexpressed, by silencing its
expression and reported that KIM-1 directly activates IL-6/STAT-3/HIF-1 axis, in turn
possibly driving angiogenesis and tumour progression. Moreover, this study found that KIM-1
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activation of IL-6/STAT-3/HIF-1, is dependent on KIM-1 ectodomain shedding (Cuadros et al.,
2014).

1.4 Rationale, Objective and Hypothesis
1.4.1 Rationale
Renal cell carcinoma (RCC) is the most common and lethal type of kidney cancer (Cohen and
McGovern, 2005). RCC originates within the proximal convoluted tubules of the kidney, and can
metastasize to the adrenal gland, nearby lymph nodes, and distant organs such as the lungs.
Despite the fact that RCC is characterized as a highly immunogenic cancer, >30% of patients
present with (local or distant) metastatic disease at initial diagnosis, with >88% of these patients
dying within 5 years (Decastro and McKiernan, 2008; Choueiri and Motzer, 2017). As of today,
there is no cure for RCC, and the current treatments are inadequate.
The primary form of treatment for localized RCC is surgical resection of the tumour. Although
this treatment is very common, the method is problematic for metastatic RCC. Current
treatments for metastatic RCC include immunotherapies (Motzer et al., 2019) and targeted
therapies (e.g. sunitinib) that focus on immune checkpoints (Motzer et al., 2013). There is a
strong demand for novel therapeutics for metastatic RCC, as the cancer is highly resistant to
many existing therapies. Immunotherapies such as anti-PDL-1/PD1 (Weinstock and McDermott,
2015), anti-CTLA-4 (Seidel, Otsuka and Kabashima, 2018), and targeted therapies such as
mTOR (Everilimus (Donskov et al., 2020)) and VEGF (Sunitinib (Ravaud et al., 2016))
inhibitors, have been shown to reduce tumour progression and overall survival of patients with
RCC (Vachhani and George, 2016). The most promising treatment to date for metastatic RCC
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are blocking antibodies targeting the immune checkpoints aimed at enhancing anti-tumour
immunity in patients: PDL-1 (Nivolumab), PD-1L (Avelumab) and CTLA-4 (Ipilimumab)
(Motzer et al., 2015, 2018). Unfortunately, response rates and major improvement in overall
survival have been limited.
A characteristic of RCC is the cell surface expression of Kidney Injury Molecule-1 (KIM-1).
KIM-1. Although KIM-1 is known to play an anti-inflammatory and reparative role in acute
kidney injury, its specific role in RCC (including metastasis) are unclear. Analysis of The Cancer
Genome Atlas (TCGA) database has shown that >90% of all patients with RCC express KIM-1,
additionally correlating with overall increased survival (Lee and Gunaratnam, 2019).

Recent findings from our team have demonstrated that tumour associated KIM-1 inhibits
metastasis. Specifically, we found that KIM-1 expression on murine Renca, and human 786-O
cells inhibits extravasation and invasion in vitro. KIM-1 expressing human 786-P cells were
found to have a significant reduction in extravasation capability in an in vivo CAM model.
Moreover, using an experimental metastasis model, we found that KIM-1 expressing Renca, and
786-O cells had significantly reduced metastasis to the lungs, independent of adaptive immunity.
Lastly, we identified two pro-metastatic, invasion, and adhesion genes, Rap1 and RAB27b, that
may be downregulated by KIM-1. Overall, our findings reveal a novel inhibitory role of KIM-1
in the metastatic cascade of RCC (Lee and Gunaratnam, 2019). These previous findings suggest
that KIM-1 may be playing a beneficial role for RCC patients. Further determining the
pathophysiological role of KIM-1 in RCC progression, may provide new insights into its
pathogenesis and potentially identify KIM-1 as a therapeutic target.
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1.4.2 Objective and Hypothesis
The objective of this study was to further understand the pathophysiological role of KIM-1 in
RCC tumour progression. Based on preliminary clinical findings from TCGA database, we
hypothesized that KIM-1 expression on RCC inhibited tumour growth and progression. To study
this, we generated murine RCC Renca cell lines to overexpress KIM-1 (KIM-1pos) or to not
express KIM-1 (KIM-1neg) through lentiviral transduction, and further investigate in vitro and in
vivo effects.

1.4.3 Specific Aims
The aims outlined in the work of this thesis are: 1) To evaluate whether KIM-1 expression alters
Renca tumour growth within immune competent syngeneic BALB/c mice. 2) Characterize the
TME of KIM-1pos vs KIM-1neg Renca tumours. And 3) Investigate potential mechanisms and
downstream targets of KIM-1. We hypothesize that KIM-1 inhibits primary tumour growth in
our subcutaneous immune competent model, that KIM-1 alters the TME allowing for a greater
anti-tumour immune response, and lastly that KIM-1 expression is able to inhibit primary tumour
growth through downstream targets similar to those found within human RCC.
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Chapter 2
2. Methods and Materials
2.1 Generation of KIM-1 Expressing Stable Cell Line Using Lentiviral
Particles
A previous master’s student from our laboratory generated our mouse cell lines utilized for the
aims of this thesis. The mouse Renca adenocarcinoma cell line (Murphy and Hrushesky, 1973)
known as Renca (CRL-2947) was purchased from American Type Culture Collection (ATCC)
and transduced with Lentiviral Open Reading Frames (ORF) particles containing empty vector or
encoding the mouse KIM-1 gene, Havcr1. The generation of these cell lines are described in
detail elsewhere. Briefly, lentiviral ORF particles containing a vector coding the mouse KIM-1
gene transcript (MR203831L3V; Origene, Rockville, MD), was used to implement the
overexpression of KIM-1 to generate Renca KIM-1pos cells. Control Lentiviral ORF particles
containing the same vector without the presence of the mouse KIM-1 gene transcript
(PS100092V; Origene, Rockville, MD), was used as a control to generate Renca KIM-1neg cells.
The lentiviral particle concentration used for transduction was determined using multiplicity of
infection (MOI) ratios. The desired MOI refers to the number of virion infectious particles to the
number of cells that are needed for stable transduction. The total number of cells per well was
multiplied by the desired MOI to get the total transducing units (TU). The TU was then divided
by the viral titre, known as the total TU/ml that is specific to the purchased virus. This
calculation provided us with an optimal volume of virus to use for the desired MOI on our Renca
cells.
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Methods for the following were performed previously by our team and was essential to the
success of this project. Renca cells were seeded in a 6-well plate and incubated for 24h at 37°C
and 5% (v/v) CO2 in complete Dulbecco's Modified Eagle Medium (DMEM; Lonza,
Walkersville, MD) with 10% (v/v) fetal bovine serum (FBS; Cat No. 12483020, Thermo Fisher
Scientific, Waltham, MA), 1% (v/v) 200uM L-glutamine (Cat No. 25-030-081, Thermo Fisher
Scientific, Waltham, MA), 1% (v/v) 100X sodium pyruvate (Cat No. 11360070, Thermo Fisher
Scientific, Waltham, MA), 1% (v/v) 100X non-essential amino acids (Cat No. 11-140-050,
Thermo Fisher Scientific, Waltham, MA) until 75% confluency had been reached. After 24 h,
complete DMEM was aspirated and replaced with fresh complete DMEM, supplemented with 8
ug/mL polybrene solution (Santa Cruz Biotechnology), along with either mouse-KIM-1 encoded
lentiviral ORF particles and/or control lentiviral ORF particles. Cells were incubated with
polybrene solution and lentiviral ORF particles for 24h at 37°C and 5% (v/v) CO2. After 24h,
medium was aspirated and replaced with fresh complete DMEM. After 72h post-transduction the
complete DMEM was aspirated and replaced with 1mL of complete DMEM supplemented with
2ug/ml of puromycin dihydrochloride (Sigma-Aldrich, Oakville, CA) per well. Replacement of
culture medium containing puromycin dihydrochloride occurred every 2-3 days for two weeks
post-transduction. After sufficient replication and subculture of positively selected cells, both
KIM-1pos and KIM-1neg Renca cells were trypsinized (Trypsin-EDTA [0.25%, Cat No.
25200072, Thermo Fisher Scientific, Waltham, MA]) and collected to confirm KIM-1 gene and
protein expression, respectively (Lee and Gunaratnam, 2019).
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2.1.2 Cell Culture
Renca cells ( KIM-1pos and KIM-1neg) were maintained according to culture methods
recommended by ATCC Renca cells in antibiotic free complete Dulbecco's Modified Eagle
Medium (DMEM; Lonza, Walkersville, MD) as defined above. Stable cell lines were maintained
with 2g/mL of puromycin dihydrochloride. Cell culture medium was aspirated and replaced
every 2-3 days with fresh complete DMEM plus 2g/mL puromycin dihydrochloride where
required. Renca cells were sub-cultured every 4-5 days using Trypsin-EDTA.

2.2 Protein Extraction
Cells were seeded in 10cm2 culture dishes (Cat No. 10062-880, VWR, Pennsylvania, USA) with
complete cell culture medium. Cells were incubated at 37°C and 5% (v/v) CO2 for 24h until
reaching ~90% confluency. Prior to cell lysis, Radioimmunoprecipitation assay buffer (RIPA
[RIPA Lysis Buffer System; sc-24948; Santa Cruz Biotechnology]) was prepared by combining
10ul of sodium orthovanadate, 10l of PMSF solution, and 10ul of protease inhibitor solution for
every 1mL of complete RIPA buffer needed (sc-24948; Santa Cruz Biotechnology). Once cells
have reached ~90% confluency, cell medium was aspirated and cells were washed with cold 1 x
PBS (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HOP4, 1.47 mM KH2PO4, pH 7.4) for 5
minutes on ice. Cold 1 x PBS was aspirated, and cells were prepared lysed using. For 100mm
culture dishes, 1mL complete RIPA buffer was evenly placed on the monolayer of cells while on
ice for 5 minutes, gently agitating the solution occasionally. Using a cell scrapper, cells were
collected from the dish and carefully transferred into microcentrifuge tubes. Lysates were then
centrifuged at 4°C at ~12,000 x g for 20 minutes. After centrifugation was complete, protein
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supernatants from samples were collected and isolated into fresh microcentrifuge tubes for
further analysis.

2.2.1 Western Blot
Whole cell lysates were collected and analyzed for protein purity and concentration using the
Pierce BCA Protein Assay Kit (Cat No. 23225, Thermo Fisher Scientific, Waltham, MA).
Protein concentrations were determined and compared to the concentrations of protein standards
provided with the kit. Lysate samples were diluted with appropriate amounts of H2O, to generate
a total concentration of 50g of protein per sample. Loading dye was prepared by combining
190l 6x sodium dodecyl sulphate (SDS) protein loading buffer (Laemmli buffer) with 10l
of -mercaptoethanol. Subsequently, 6l of prepared loading dye solution were added to each
sample to reduce disulphide bonds. Samples were then boiled for 5 minutes at 95°C to further
denature protein structures. Samples were then loaded onto 10% SDS-polyacrylamide gels.
Protein samples were then separated based on charge-to-mass ratio and then transferred onto a
polyvinylidene difluoride membrane (Millipore, Billerica, MA) for 50 minutes at 90 V (Bio-Rad,
Hercules, CA). After 50 minutes, membranes were blocked with a 3% (w/v) BSA (bovine serum
albumin; Cat No. AD0023, Bio Basic, Markham, ON) solution made in 1 x TBST (Tris-buffered
saline, in 1mL of 0.2% Tween-20Cat No. BP337-500, Fisher Bioreagents, Waltham, MA).
Membranes were then incubated overnight at 4°C on a rotational shaker with either goat antimouse KIM-1 primary antibody (1:2000; Cat No. AF1817, R& D Systems, Minneapolis, MN) or
anti-human KIM-1 (AKG; [Han et al., 2002]) targeting the extracellular domain of KIM-1.
Glyceraldehyde phosphate dehydrogenase (GAPDH) was used (loading control) was detected
using anti-mouse GAPDH (65C) antibody (1:1500; Santa Cruz Biotechnology). After overnight
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incubation, membranes were then washed 4 times on a rotational shaker in 1 x TBST with
changes every 7 minutes. Membranes were then incubated with appropriate secondary antibodies
conjugated with horseradish peroxidase (1:20000; Jackson Immunoresearch Laboratories, West
Grove, PA) in 3% BSA blocking buffer for 1h in the dark, at room temperature. After secondary
antibody incubation and washing in 1 x TBST for 5 minutes for 3 times, proteins were then
visualized using Luminata Forte Western HRP Substrate (EMD Milipore) and developed on the
Licor C-digital imaging device. Western blot images were captured using Image Studio Lite.

2.3 RNA Isolation
Cell and tissue RNA were extracted on ice using TriZol Isolation Reagent (Cat No. 15596018;
Life Technologies) using approximately 500l-1mL per sample depending on cell confluency
and/or tissue size, respectively. For every 500l of TriZol, 100l of chloroform was added to
facilitate phase separation. Samples were briefly vortexed and incubated on ice for 10 minutes
before centrifugation at ~ 12,000 x g for 20 minutes at 4°C. After centrifugation and phase
separation had occurred, the aqueous layer was removed carefully and placed into a fresh
microcentrifuge tube. For every 500l of TriZol, 100l of isopropanol was added to the aqueous
layer to facilitate precipitation of RNA. Samples were briefly vortexed and incubated on ice for
10 minutes before centrifugation at ~ 12,000 x g for 10 minutes at 4°C. Supernatants were
removed from the samples and discarded. Pellets were washed with 70% ethanol (EtOH) diluted
in Diethyl Pyrocarbonate (DEPC) -treated H2O (RNase free water) and centrifuged at ~ 7,500 x g
for 5 minutes at 4°C. Supernatant was removed from samples and discarded. RNA pellets were
resuspended in DEPC-treated H2O and heated in a water bath at 56°C for 10 minutes. RNA was
quantified and analyzed for purity using a spectrophotometer (260nm and 280nm;
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MulltishkanTM GO Microplate Spectrophotometer; Thermo Fisher Scientific, Waltham, MA).
One microliter of total RNA was placed onto Microplate and absorbances were used to calculate
purity and concentration of RNA. One microgram of total RNA was combined with 4L of
qSCRIPT cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) to synthesize cDNA. The
reaction was facilitated using a MyCyclerTM Thermal Cycler (Bio-Rad, Hercules, CA). cDNA
was further stored at -20°C until further analyzation.

2.3.1 Real Time Quantitative PCR (RT-qPCR)
cDNA samples were used to perform RT-qPCR using SYBR green reagents (Thermo Fisher
Scientific, Waltham, MA). Reaction mixtures were placed in a v-shaped 96-well plate, each well
containing 10L of SYBR green, 4.6L of DEPC-treated water, 5l of diluted cDNA in DEPCtreated water (ratio 1:10), and 0.2L of both 10M forward and reverse strand primers made by
myself. Various primers were used to detect varying gene transcriptions in both cell lines and
tissues shown in Table 1. Target genes were normalized using GAPDH to counterbalance any
PCR variations present. Relative gene expression was calculated using 2- CT method.

2.3.2 RNA Sequencing
Renca cell line preparation for RNA sequencing was performed by Brad Shrum. Previously
generated data showing discrepancies between our Renca cells [ KIM-1pos and KIM-1neg] (Lee
and Gunaratnam, 2019), was re-analyzed for this project. RNA sequencing was performed by
London Genomics Centre with the help of Dr. Rob Hegele at the Robarts Research Institute at
Western University. RNA was extracted and isolated, with subsequent cDNA synthesis
performed as described above on both KIM-1pos and KIM-1neg Renca cell lines. Illumina
sequencing adapter sequences were used, and libraries were sequenced using the Illumina
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NextSeq 500 sequencer (Illumina Inc., San Diego, CA). All sequence data was generated and
analyzed by Partek Flow Software (Partek Inc., St. Louis, MO). Stringencies for data analysis
was instilled within the bioinformatic pipeline to only compare genes with a p-value < 0.05, and
to exclude fold changes between 1.5 and -1.5. Differential genes were analyzed through gene
enrichments; allowing for the grouping of like genes that comply to a specific cellular function,
as well as gene pathways. Bioinformatic pipelines were further specified by exploring for
functional cellular differences within both gene enrichments, and gene pathways.

2.4 The Human Cancer Genome Atlas (TCGA) Database
All raw TCGA patient data was extrapolated and organized into a working excel spreadsheet by
colleague Audrey Champagne. KIPAN patient database was used to complete human RCC and
KIM-1 analyses. KIPAN database contains patient information from those diagnosed with
ccRCC (KIRC or Kidney Clear Cell Carcinoma), pRCC (KIRP or Kidney Papillary Carcinoma),
and Chromophobe RCC (KICH or Chromophobe Carcinoma). Working spreadsheet was then
filtered to select data based upon analyses needed. Data was then transferred into
GraphPad/Prism 8 in order to perform statistical analyses and generate graphical representations.

2.5 Mice
Animal protocol (2018-147) outlining all the studies contained in this thesis were approved by
Western University's Animal Care Committee and in compliance with the guidelines set by
Canadian Council of Animal Care. Female wild-type (WT) BALB/c mice were purchased from
Charles River Laboratory (Wilmington, MA). Female mice are the common model to use for
oncological research (Lee et al., 2018), along with having a higher tolerance to kidney injury in
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comparison to male mice (Hu et al., 2009). All mice were kept in shoebox cages with easy
access to water and mouse chow pellets. Immune-deficient recombinase-activating gene (Rag 1-/) null mice were purchased from Jackson Laboratory (Bar Harbor, ME) and housed in the West
Valley pathogen-free barrier facility at Western University. These mice were kept in shoebox
microisolator cages with easy access to water and mouse chow pellets. Mouse holding rooms
were maintained at a constant temperature of 22°C with timed 12 h light and 12 h dark periods.

Experimental mice were monitored every 2-3 days for health and behavioral monitoring. All
physiological and behavioral changes were monitored and recorded for all experimental animals.
After experiments were complete, all mice were euthanized using CO 2. Collection of samples
needed per experiments occurred post-mortem. Mouse holding rooms were maintained at a
constant temperature of 22°C with timed 12 h light and 12 h dark periods.

2.6. Experimental Tumour Models
2.6.1 Subcutaneous Model of RCC Tumours
To study tumour growth of RCC cells with the overexpression of KIM-1 (Renca KIM-1pos) or
the absent expression of KIM-1 (Renca KIM-1neg) – Renca cell lines were injected into immune
competent BALB/c mice. Prior to injections, Renca cells were cultured in 15cm dishes at a
seeding concentration of 1 x 106cells/mL in complete DMEM. Stable expression of the
transduced cell lines was maintained with 2g/mL of puromycin dihydrochloride. Medium was
aspirated and replaced with fresh complete DMEM and puromycin dihydrochloride every 2-3
days until 80%-90% confluency had been reached. Once 80%-90% confluent, cells were washed
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with 10mL of warmed 1xPBS, and subsequently replaced with 5mL of Trypsin-EDTA for 5
minutes in 37°C, 5% (v/v) CO2 incubator. 10mL of complete DMEM was then added to cells to
neutralize trypsin. Cells were then spray washed to remove any adherent cells from the culture
dish surface. Collected cells were then centrifuged at 21°C, 400 x g, for 3 minutes. After
centrifugation, the supernatant was aspirated and discarded, and cell pellets were then
resuspended in complete DMEM in preparation for cell counting. Cells were counted using a 1:1
dilution; 10L of trypan blue (0.4%) (Cat No. 97063-702, VMR International) with 10L of
suspended cells onto a hemocytometer (Fisher Scientific, Waltham, MA). Cell viability was
assessed using Trypan blue exclusion and cell a viability of >95% was observed before injection.
After determining the total cell number, cells were resuspended at a concentration of 1x106
cells/100L in a 1:1 ratio of 1xPBS and Corning MatrigelTM growth factor reduced (GFR)
Membrane Matrix (Cat No. CB-40230C, Thermo Fisher Scientific, Waltham, MA). Cells in PBS
and MatrigelTM were kept on ice to avoid solidification of matrix solution. Mice were sedated
using 2% isoflurane for medium depth anesthesia following standard operating procedures prior
to and during injections. Renca cells were resuspended at 1 x 106 cells/100L in either 1 x PBS
alone (No MatrigelTM) or in a 1:1 dilution of 1 x PBS with Corning (GFR) MatrigelTM Membrane
at a volume of 100L/injection. One hundred microliters of each cell line were placed into an
intermediary microcentrifuge tube, and subsequently drawn up into an 1/2 inch 28-gauge insulin
syringe (Becton Dickinson, Franklin Lakes, NJ). Cells were either injected bilaterally, where
Renca KIM-1pos and Renca KIM-1neg cells were injected into opposite flanks of the same mouse,
or cells were injected unilaterally where only one cell line was given per mouse. Prior to
injection, needles were inserted bevel up under the skin, and gently moved around to remove
facia. This allowed for cell suspension with Matrigel TM membrane to solidify in a more unified
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shape. Mice were monitored every day for the first 72h post injection, and then every 3-4 days
afterwards for a duration of 21 days. Mice were then euthanized using a CO 2 chamber, and
tumours were removed using sterile surgical instruments, and collected for further analysis.

2.6.2 Renal Orthotopic Model
To study tumour growth of Renca KIM-1pos vs Renca KIM-1neg cells in a clinically relevant
model of RCC – Renca cells were injected directly into the kidney. Specifically, either Renca
KIM-1pos or Renca KIM-1neg cells were injected orthotopically into the subcapsular region of the
left kidney of 6-10-week-old female WT BALB/c mice. Prior to injections, Renca cells were
cultured, collected, and counted using the methods as described above. After determining the
total cell number, cells were resuspended at a concentration of 2.5 x 105 cells/100L in a 1:1
ratio of 1xPBS and Corning MatrigelTM GFR Membrane Matrix. Cells in PBS and MatrigelTM
were kept on ice to avoid solidification of matrix solution. Mice were given slow-release
buprenorphine (0.6mg/kg, Chiron Compounding Pharmacy, Guelph, ON) analgesics, and
subsequently isoflurane sedation prior to surgical injections. Mouse fur was then shaved at the
region of interest on the left flank, and surgical area was sterilized with iodine solution and 70%
ethanol. Skin barrier and muscle layer were incised using sterile surgical instruments. Left
kidneys were exposed and 30l of cells in MatrigelTM suspension were injected into the
subcapsular region of the left kidney. All incisions were closed using sutures and staples
according to our standard operating procedures outlined in animal our protocol. Mice were kept
under a heat lamp until conscious and monitored 24 h post-injection, and every 2 days following.
After 21 days, mice were euthanized using a CO2 chamber, tumour bearing kidneys and lungs
were removed for further analysis of primary and secondary tumour growth, respectively.
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2.7 Tumour Immunofluorescence Microscopy
2.7.1 Sample Preparation
All tissue samples were fixed in Periodate-Lysine-Paraformaldehyde (PLP) solution, made one
day before use. Solution was made by first preparing a phosphate buffer containing 3:1 parts
monobasic sodium phosphate and dibasic sodium phosphate diluted in double distilled H2O
(ddH2O). Phosphate buffer was autoclaved and cooled to room temperature prior to preparing
complete fixative solution. Once phosphate buffer reached room temperature, L-Lysine (>98%,
Cat No. L5501-25G, Sigma-Aldrich, Oakville, CA) and Paraformaldehyde (PFA, Cat No.
PB0684.SIZE.500g, Bio Basic, Markham, ON) were diluted in ddH2O and combined. Sodium
Periodate (>99.8%, Cat No. 311448-100G, Sigma-Aldrich, Oakville, CA) was then added to
mixture. Using the prepared phosphate buffer, the total volume was then brought up to 500mL or
1L depending on how much solution was needed. PLP was kept at 4°C, in the dark until use
(Appendix A 2).

Subcutaneous and renal subcapsular experimental tumours were both collected to analyze
immune infiltration using immunofluorescence. After euthanization, tissues were collected in
15mL Falcon Centrifuge tubes (Cat No. 14-959-49B, Thermo Fisher Scientific, Waltham, MA),
containing 10mL of PLP. Samples incubated in PLP for a maximum of 24 h, on a rotational
shaker at 4°C, in the dark. After 24 h, samples were removed from PLP and gently rinsed with
phosphate buffer before subjecting tissues to a sucrose gradient. Sucrose solutions were prepared
the same day to ensure no bacterial contaminations occurred. Sucrose gradients were prepared
using phosphate buffer (3:1 monobasic, dibasic sodium phosphate) with (v/v) 10%, 20% and
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30% sucrose (>99.5%, Cat No. S7903-250G, Sigma-Aldrich, St. Louis, MO). All samples were
placed in each gradient beginning at 10%, then subsequently 20%, and 30%, for one hour at a
time or until tissues sank. After completing the three sucrose gradient steps, tissues were
removed from sucrose and pat dried. A freezing bath was prepared using a metal tray placed in a
styrofoam box containing dry ice with 10mL of 95% (v/v) ethanol. Approximately 5mL of 2Methylbutane Reagent (>99%) (Cat No. M32631-4L, Sigma-Aldrich, Oakville, CA) was added
to the metal tray and allowed to reach the appropriate freezing temperature. Tissues were then
placed in OCT compound (Cat No. 23730571, Thermo Fisher Scientific, Waltham, MA) in tissue
cassettes. Tissues completely submerged in OCT compound within cassettes were placed onto
metal tray until OCT compound froze around tissues. Cassettes were then wrapped in cling wrap
and covered with tin foil prior to storage in the -80°C to avoid samples drying out.

2.7.2 Co-Immunofluorescence
Frozen OCT blocks containing tissue samples were sent off to Weihua Liu in the Department of
Pathology at The University of Western Ontario. Samples were removed from histology tissue
cassettes and placed onto a cryostat and sliced at a size of 7-10 microns. Each sample is then
placed onto a positively charged glass slide (Cat No. 22-037-246, Fisher Scientific, Waltham,
MA) and mounted appropriately. Fluorophore conjugated antibodies were applied to samples CD3+ (SP7) (1:200, Cat No. NB600-1441SS, Novus Biologicals), CD4+ (1:200, Cat No.
MABF575, Millipore Sigma, Burlington, MA), and CD8+ (1:400, Cat No. 100727, Bio Legend,
San Diego, CA) to analyze co-immunofluorescence (CD3+, CD3+CD4+, and CD3+ CD8+).
Tumour samples were analyzed for immune infiltrate population frequency and distribution
using Cell Counter plugin in Fiji (ImageJ) Software, normalized to measured areas of focus (per
square micron of tissue).
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2.7.3 Immunohistochemistry
Tissue samples that were subjected to immunohistochemical staining were collected from mice,
and directly placed into 15mL Falcon tubes (Cat No. 14-959-49B, Thermo Fisher Scientific,
Waltham, MA) containing 10% formalin buffered solution (Cat No. HT501128-4L, SigmaAldrich, Oakville, CA). Tissue samples were incubated in 10% formalin for 72 h for tissue
fixation. After 72 h, samples were moved from 10% formalin to 70% ethanol prior to analysis.
Samples were then embedded in paraffin blocks within tissue cassettes. After hardening
occurred, embedded tissues were sliced at 7-10 microns, and placed onto a positively charged
glass slide. Samples were mounted properly and stained with either hematoxylin and eosin
(H&E) or Masson’s Trichrome staining for further analysis.
Quantification of histological sections of KIM-1pos and KIM-1neg Renca tumour capsules were
measured using brightfield microscope analyzing for distance width measurements using NISElements Nikon Software. All tumour capsules were measured at 100x and normalized to total
visualized area imaged by the microscope software. Tumour capsule measurements were
evaluated using distance between two points; from the inner-most to the outer-most collagen
layer of the capsule. Capsules were measured at five randomized locations throughout each
tumour sample, and widths were averaged for final measurements.

2.8 Statistical Analysis
All data is presented as a mean ± standard error of the mean (SEM). Normality was assessed
using normality and lognormality tests. Between group differences in standard error of the
means (SEM) were assessed using Student’s t- or Kruskal-Wallis tests for parametric and
nonparametric data, respectively. Survival was plotted using Kaplan Meir curves, and groups
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compared with log-rank test. Normality Lognormality statistical analysis was used to compare
matched normal vs adjacent tumour tissue from TCGA patient database. A two-tailed alpha
<0.05 was considered statistically significant. Statistical analyses were performed using
GraphPad Prism, version 8.

2.9 Sample Size Calculation
Sample size calculation for tumour growth studies was calculated prior to experiments to
determine proper N to observe significance. N mice in each group would provide >=80% power
to detect at least a 30% difference in tumour growth between groups, two-sided alpha = 0.05. N
mice per group would provide >=80% power to detect at least a difference of at least xx standard
deviations, two-sided alpha = 0.05).
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Chapter 3
3. Results
3. 1 KIM-1 (Havcr1) mRNA is expressed at all stages of RCC and increases
overall patient survival
To investigate how KIM-1 expression may impact the survival of patients diagnosed with RCC,
we utilized The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/tcga). KIPAN
patient database including data from ccRCC, pRCC, and Chromophobe RCC patients was
extracted. For our analysis, the KIRC (Kidney Clear Cell Carcinoma) and KIRP (Kidney
Papillary Carcinoma) databases were combined due to KIM-1 upregulation being found in only
ccRCC and pRCC patients (Zhang et al., 2014). I analyzed ccRCC or pRCC patient data in
correlation with tumour associated KIM-1 (Havcr1) mRNA expression. First, I analyzed
differences of KIM-1 expression between affected RCC tumours, and adjacent unaffected or
normal tissue. Results showed that KIM-1 mRNA expression was significantly increased within
tumours compared to normal adjacent tissue (Fig 1A). I then stratified patients according to the
American Joint Committee on Cancer (AJCC) tumour-node-metastasis (TNM) staging system
(Stages 1 to 4) to determine if KIM-1 expression varied with stage (The American Joint
Committee on Cancer (AJCC), 2017). Compared to normal adjacent tissue, the KIM-1 mRNA
expression level was significantly increased in tumours at all stages of RCC (Fig 1B). Finally,
patients with tumours having KIM-1 expression in the top 50th percentile had significantly
improved survival compared to patients with tumours having KIM-1 expression below the 50th
percentile in a KIRC and KIRP combined analyses (median survival = 25% vs. 50%,
respectively, p <0.0001) (Fig 1C). Separate analyses of overall survival of KIRC and KIRP alone
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were completed to evaluate discrepancies between tumour types. KIM-1 expression was found to
significantly increase overall survival of KIRC patients (Fig 1D), but not KIRP patients (Fig 1E).

A.

C.

B.
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Figure 1. TCGA RNA Sequencing data reveals HAVCR1 (KIM-1) mRNA is expressed at all
stages of RCC and increased expression correlates to increased survival of KIRC (Kidney Clear
Cell Carcinoma) and KIRP (Kidney Papillary Carcinoma) patients.
A. Comparison of KIM-1 mRNA expression within non-paired normal adjacent tissue vs tumour
tissue of KIRC and KIRP RCC patients (Normal: n = 129, Tumour: n = 823) (****, P<0.0001,
Mann-Whitney t-test). B. KIM-1 mRNA expression in KIRC and KIRP RCC tumour stages vs
normal adjacent tissue (Normal: n = 129, I: n = 439, II: n = 78, III: n = 175, IV: n = 99) (****,
P<0.0001, Kruskal-Wallis statistical analysis). C. Overall KIRC and KIRP patient survival vs
KIM-1 mRNA expression using 50% low/high expression cut-offs (Low: n = 376, High: n =
441) (**, p = 0.0059; Kaplan-Meier statistical analysis). D. Overall KIRC patient survival vs
KIM-1 mRNA expression using 50% low/high expression cut-offs (Low: n = 259, High: n =
272) (**, p = 0.0019; Kaplan-Meier statistical analysis). E. Overall KIRP patient survival vs
KIM-1 mRNA expression using 50% low/high expression cut-offs (Low: n = 117, High: n =
169) (NS, p = 0.5650, Kaplan-Meier statistical analysis).
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3.2 Expression of several collagen genes is increased within human RCC
tumour tissue, in comparison to normal adjacent tissue
Extracellular matrix (ECM) and collagen properties are widely studied in terms of its effects on
tumour progression and metastasis (Fang et al., 2014). Thus, I investigated the correlation
between collagen and KIM-1 expression in RCC patients with ccRCC and pRCC from TCGA.
Collagen genes of interest; COL1A1, COL1A2, COL6A1, COL6A2, and COL23A1 were selected
based off previous research of collagen in RCC (Wan et al., 2015; Xu et al., 2017; Majo et al.,
2020). First, I analyzed the expression of the above collagen genes and compared their
expression in RCC tumour tissue vs normal adjacent tissue for each patient. Results showed that
COL1A1, COL1A2, COL6A1, COL6A2, and COL23A1 mRNA expression were all significantly
increased within RCC tumour tissues compared to matched normal adjacent tissues (Fig 2A-E).
A.

B.
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C.

D.

E.

Figure 2. TCGA RNA Sequencing database reveals increased collagen mRNA expression in
RCC tumour tissue vs normal adjacent tissue using KIRC (Kidney Clear Cell Carcinoma) and
KIRP (Kidney Papillary Carcinoma) patient databases.
Paired comparison of normal adjacent tissue vs matched patient tumour tissues reveals several
collagen genes A. Col1A1, B. Col1A2, C. Col6A1, D. Col6A2 and E. Col23A1 mRNA
expression increased in RCC tumour tissues (n=104/group) (****, P<0.0001; Normality
Lognormality statistical analysis).

43

3. 3 mRNA expression of KIM-1 vs serval collagen genes, have no clear
correlation in human RCC patients
To investigate the relationship between KIM-1 and collagen gene mRNA expression within
human RCC patients, I analyzed our previously used collagen genes of interest (COL1A1,
COL1A2, COL6A1, COL6A2, and COL23A1) along with 29 genes selected from a group of
genes termed tumour matrisome index (TMI) by Su Bin Lim and team (Lim et al., 2019). The
TMI was previously used to perform a multi-component analysis of ECM genes in a pan-cancer
study to elucidate differential tumour immune responses. Using our previous genes of interest as
well as the 29 genes within the TMI from Su Bin Lim, I analyzed correlations between collagen
genes vs KIM-1 mRNA expression within human RCC patients (Lim et al., 2019) (Fig 3A).
TCGA RNA-seq data from KIPAN databases (KIRC, KIRP and KICH) were used in order to
correlate comparative mRNA expression levels. Tumour KIM-1 expression in the top 25th
percentile, and bottom 25th percentile were compared using Spearman’s rank order correlation
co-efficient to elucidate whether each collagen gene had a negative or positive correlation to
KIM-1 (Havcr1). Results showed many correlations between the signature and KIM-1, yet no
clear correlation trends between KIM-1 (Havcr1) and the TMI signatures (Fig 3B).
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A.
Tumour Matrisome Index (TMI)
Genes (Su Lin Bim et al.,)
ABI3BP
ADAMTS8
CD36
CHRDL1
COL10A1
COL11A1
COL6A6
CPB2
CTHRC1
CXCL13
CXCL2
FCN3
GREM1
HHIP
IL6
LPL
MAMDC2
MMP1
MMP12
OGN
PCOLCE2
S100A12
S100A2
SFTPA2
SFTPC
SFTPD
SPP1
TNNC1
WIF1

B.
Variables
HAVCR1
ABI3BP
ADAMTS8
CD36
CHRDL1
COL10A1
COL11A1
COL6A6
CPB2
CTHRC1
CXCL13
CXCL2
FCN3
GREM1
HHIP
IL6
LPL
MAMDC2
MMP1
MMP12
OGN
PCOLCE2
S100A12
S100A2
SFTPA2
SFTPC
SFTPD
SPP1
TNNC1
WIF1
COL1A1
COL1A2
COL23A1
COL6A1
COL6A2

HAVCR1
1
0.428
-0.089
0.072
-0.068
-0.093
0.007
-0.173
-0.026
0.114
0.149
0.142
-0.029
-0.115
0.019
-0.133
-0.104
-0.061
-0.070
-0.122
-0.157
0.151
0.055
-0.364
-0.031
-0.100
-0.129
0.275
-0.391
-0.023
0.100
0.085
0.406
-0.203
0.096

ABI3BP
0.428
1
0.065
0.000
0.083
-0.022
0.104
-0.020
-0.034
0.135
-0.003
0.236
-0.083
-0.023
0.162
-0.017
-0.075
0.086
-0.096
-0.066
-0.045
0.062
0.050
-0.097
-0.035
-0.157
0.035
0.206
-0.183
0.033
0.073
0.107
0.314
-0.078
0.136

ADAMTS8
-0.089
0.065
1
-0.073
0.332
0.175
0.132
0.229
0.076
-0.072
-0.118
0.139
0.058
0.306
0.316
0.191
0.172
0.303
-0.032
-0.024
0.398
0.062
-0.007
0.304
0.122
0.013
0.289
-0.043
0.369
0.281
0.021
0.100
-0.027
0.017
0.122

CD36
0.072
0.000
-0.073
1
-0.213
0.163
0.254
0.005
0.024
0.493
0.421
0.140
0.708
0.161
-0.137
0.304
0.570
-0.102
0.452
-0.052
0.250
0.496
0.461
-0.540
-0.032
-0.258
0.268
-0.527
-0.394
-0.208
0.452
0.494
0.556
0.140
0.424

CHRDL1
-0.068
0.083
0.332
-0.213
1
0.362
0.240
0.242
0.071
0.006
0.001
0.112
-0.118
0.513
0.351
0.337
0.070
0.532
0.024
0.254
0.434
0.098
-0.017
0.374
0.057
0.032
0.072
0.127
0.436
0.349
0.059
0.146
-0.240
-0.018
0.020

COL10A1
-0.093
-0.022
0.175
0.163
0.362
1
0.719
0.239
0.044
0.491
0.336
0.083
0.238
0.596
0.233
0.469
0.149
0.256
0.283
0.281
0.522
0.229
0.161
0.090
0.048
-0.025
0.005
-0.074
0.103
0.192
0.607
0.614
0.025
0.354
0.427

COL11A1
0.007
0.104
0.132
0.254
0.240
0.719
1
0.125
0.079
0.619
0.370
0.218
0.275
0.541
0.196
0.507
0.101
0.193
0.365
0.293
0.368
0.224
0.205
-0.015
0.038
-0.131
0.065
-0.083
-0.063
0.043
0.715
0.687
0.207
0.428
0.584

COL6A6
-0.173
-0.020
0.229
0.005
0.242
0.239
0.125
1
-0.003
0.008
-0.019
-0.037
-0.013
0.285
0.208
0.158
0.121
0.213
0.054
0.090
0.327
0.045
-0.105
0.157
0.006
-0.029
0.039
-0.141
0.269
0.181
0.102
0.120
-0.172
0.102
0.051

CPB2
-0.026
-0.034
0.076
0.024
0.071
0.044
0.079
-0.003
1
0.127
0.122
0.104
0.050
0.067
0.063
0.065
0.039
0.015
0.046
0.037
0.054
0.062
0.023
0.029
0.059
-0.017
0.035
0.024
-0.040
0.019
0.057
0.091
0.078
-0.001
0.099

CTHRC1
0.114
0.135
-0.072
0.493
0.006
0.491
0.619
0.008
0.127
1
0.577
0.289
0.373
0.383
-0.008
0.456
0.080
-0.028
0.460
0.224
0.240
0.308
0.381
-0.282
0.026
-0.243
0.057
-0.179
-0.341
-0.155
0.779
0.732
0.484
0.446
0.721

CXCL13
0.149
-0.003
-0.118
0.421
0.001
0.336
0.370
-0.019
0.122
0.577
1
0.213
0.367
0.274
-0.079
0.334
0.029
-0.221
0.313
0.195
0.182
0.349
0.335
-0.343
-0.009
-0.175
-0.066
-0.224
-0.297
-0.111
0.537
0.492
0.439
0.275
0.512

CXCL2
0.142
0.236
0.139
0.140
0.112
0.083
0.218
-0.037
0.104
0.289
0.213
1
0.109
0.136
0.084
0.458
0.058
0.052
0.104
0.184
0.050
0.204
0.288
0.009
0.061
-0.161
0.129
0.087
-0.117
0.028
0.225
0.203
0.325
0.111
0.305

FCN3
-0.029
-0.083
0.058
0.708
-0.118
0.238
0.275
-0.013
0.050
0.373
0.367
0.109
1
0.132
-0.035
0.284
0.502
-0.105
0.313
-0.052
0.332
0.540
0.423
-0.327
-0.059
-0.161
0.307
-0.445
-0.238
-0.109
0.394
0.443
0.491
0.186
0.399

GREM1
-0.115
-0.023
0.306
0.161
0.513
0.596
0.541
0.285
0.067
0.383
0.274
0.136
0.132
1
0.299
0.542
0.217
0.364
0.361
0.324
0.635
0.200
0.169
0.160
0.126
-0.067
0.104
-0.115
0.243
0.217
0.483
0.530
-0.011
0.172
0.364

HHIP
0.019
0.162
0.316
-0.137
0.351
0.233
0.196
0.208
0.063
-0.008
-0.079
0.084
-0.035
0.299
1
0.179
0.119
0.308
-0.021
0.107
0.338
0.174
-0.013
0.216
0.041
-0.027
0.139
0.082
0.255
0.269
0.136
0.192
-0.030
0.019
0.127

IL6
-0.133
-0.017
0.191
0.304
0.337
0.469
0.507
0.158
0.065
0.456
0.334
0.458
0.284
0.542
0.179
1
0.243
0.206
0.386
0.345
0.351
0.327
0.314
0.096
0.110
-0.098
0.218
-0.094
0.040
0.105
0.474
0.490
0.104
0.253
0.400

LPL
-0.104
-0.075
0.172
0.570
0.070
0.149
0.101
0.121
0.039
0.080
0.029
0.058
0.502
0.217
0.119
0.243
1
0.170
0.258
-0.023
0.376
0.379
0.254
-0.136
0.035
-0.076
0.304
-0.400
0.018
0.020
0.118
0.237
0.169
-0.068
0.100

MAMDC2
-0.061
0.086
0.303
-0.102
0.532
0.256
0.193
0.213
0.015
-0.028
-0.221
0.052
-0.105
0.364
0.308
0.206
0.170
1
-0.018
0.097
0.407
-0.006
-0.039
0.322
0.066
0.049
0.058
0.058
0.341
0.262
0.049
0.140
-0.269
-0.062
-0.020

MMP1
-0.070
-0.096
-0.032
0.452
0.024
0.283
0.365
0.054
0.046
0.460
0.313
0.104
0.313
0.361
-0.021
0.386
0.258
-0.018
1
0.204
0.246
0.294
0.303
-0.142
0.031
-0.147
0.166
-0.251
-0.118
-0.072
0.430
0.412
0.225
0.141
0.314

MMP12
-0.122
-0.066
-0.024
-0.052
0.254
0.281
0.293
0.090
0.037
0.224
0.195
0.184
-0.052
0.324
0.107
0.345
-0.023
0.097
0.204
1
0.109
0.054
0.108
0.160
0.027
0.055
-0.095
0.136
0.115
0.046
0.273
0.255
-0.084
0.214
0.161

OGN
-0.157
-0.045
0.398
0.250
0.434
0.522
0.368
0.327
0.054
0.240
0.182
0.050
0.332
0.635
0.338
0.351
0.376
0.407
0.246
0.109
1
0.313
0.186
0.104
0.043
-0.076
0.150
-0.290
0.291
0.260
0.392
0.475
0.053
0.149
0.298

PCOLCE2
0.151
0.062
0.062
0.496
0.098
0.229
0.224
0.045
0.062
0.308
0.349
0.204
0.540
0.200
0.174
0.327
0.379
-0.006
0.294
0.054
0.313
1
0.401
-0.281
-0.036
-0.206
0.226
-0.236
-0.141
0.106
0.293
0.360
0.441
0.043
0.303

S100A12
0.055
0.050
-0.007
0.461
-0.017
0.161
0.205
-0.105
0.023
0.381
0.335
0.288
0.423
0.169
-0.013
0.314
0.254
-0.039
0.303
0.108
0.186
0.401
1
-0.189
0.038
-0.135
0.126
-0.205
-0.177
-0.081
0.317
0.342
0.410
0.103
0.325

S100A2
-0.364
-0.097
0.304
-0.540
0.374
0.090
-0.015
0.157
0.029
-0.282
-0.343
0.009
-0.327
0.160
0.216
0.096
-0.136
0.322
-0.142
0.160
0.104
-0.281
-0.189
1
0.068
0.158
0.038
0.258
0.585
0.323
-0.251
-0.247
-0.555
-0.024
-0.240

SFTPA2
-0.031
-0.035
0.122
-0.032
0.057
0.048
0.038
0.006
0.059
0.026
-0.009
0.061
-0.059
0.126
0.041
0.110
0.035
0.066
0.031
0.027
0.043
-0.036
0.038
0.068
1
0.168
0.126
0.051
0.012
0.049
-0.020
-0.028
-0.003
-0.047
0.027

SFTPC
-0.100
-0.157
0.013
-0.258
0.032
-0.025
-0.131
-0.029
-0.017
-0.243
-0.175
-0.161
-0.161
-0.067
-0.027
-0.098
-0.076
0.049
-0.147
0.055
-0.076
-0.206
-0.135
0.158
0.168
1
-0.091
0.167
0.177
0.038
-0.164
-0.174
-0.299
-0.013
-0.226

SFTPD
-0.129
0.035
0.289
0.268
0.072
0.005
0.065
0.039
0.035
0.057
-0.066
0.129
0.307
0.104
0.139
0.218
0.304
0.058
0.166
-0.095
0.150
0.226
0.126
0.038
0.126
-0.091
1
-0.182
0.057
0.019
0.027
0.094
0.191
-0.001
0.114

SPP1
0.275
0.206
-0.043
-0.527
0.127
-0.074
-0.083
-0.141
0.024
-0.179
-0.224
0.087
-0.445
-0.115
0.082
-0.094
-0.400
0.058
-0.251
0.136
-0.290
-0.236
-0.205
0.258
0.051
0.167
-0.182
1
0.056
0.089
-0.197
-0.224
-0.218
-0.130
-0.206

TNNC1
-0.391
-0.183
0.369
-0.394
0.436
0.103
-0.063
0.269
-0.040
-0.341
-0.297
-0.117
-0.238
0.243
0.255
0.040
0.018
0.341
-0.118
0.115
0.291
-0.141
-0.177
0.585
0.012
0.177
0.057
0.056
1
0.311
-0.249
-0.188
-0.495
-0.056
-0.282

WIF1
-0.023
0.033
0.281
-0.208
0.349
0.192
0.043
0.181
0.019
-0.155
-0.111
0.028
-0.109
0.217
0.269
0.105
0.020
0.262
-0.072
0.046
0.260
0.106
-0.081
0.323
0.049
0.038
0.019
0.089
0.311
1
-0.099
-0.047
-0.219
-0.132
-0.116

COL1A1
0.100
0.073
0.021
0.452
0.059
0.607
0.715
0.102
0.057
0.779
0.537
0.225
0.394
0.483
0.136
0.474
0.118
0.049
0.430
0.273
0.392
0.293
0.317
-0.251
-0.020
-0.164
0.027
-0.197
-0.249
-0.099
1
0.911
0.419
0.571
0.794

COL1A2
0.085
0.107
0.100
0.494
0.146
0.614
0.687
0.120
0.091
0.732
0.492
0.203
0.443
0.530
0.192
0.490
0.237
0.140
0.412
0.255
0.475
0.360
0.342
-0.247
-0.028
-0.174
0.094
-0.224
-0.188
-0.047
0.911
1
0.409
0.484
0.756

COL23A1
0.406
0.314
-0.027
0.556
-0.240
0.025
0.207
-0.172
0.078
0.484
0.439
0.325
0.491
-0.011
-0.030
0.104
0.169
-0.269
0.225
-0.084
0.053
0.441
0.410
-0.555
-0.003
-0.299
0.191
-0.218
-0.495
-0.219
0.419
0.409
1
0.107
0.509

COL6A1
-0.203
-0.078
0.017
0.140
-0.018
0.354
0.428
0.102
-0.001
0.446
0.275
0.111
0.186
0.172
0.019
0.253
-0.068
-0.062
0.141
0.214
0.149
0.043
0.103
-0.024
-0.047
-0.013
-0.001
-0.130
-0.056
-0.132
0.571
0.484
0.107
1
0.712

COL6A2
0.096
0.136
0.122
0.424
0.020
0.427
0.584
0.051
0.099
0.721
0.512
0.305
0.399
0.364
0.127
0.400
0.100
-0.020
0.314
0.161
0.298
0.303
0.325
-0.240
0.027
-0.226
0.114
-0.206
-0.282
-0.116
0.794
0.756
0.509
0.712
1
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Figure 3. Correlogram examining the correlation between tumour KIM-1 and collagen
signatures mRNA expression using TCGA KIPAN patient databases.
A. List of TMI genes extrapolated from Su Bin Lim and team used in correlation analysis (Lim
et al., 2019), along with several collagen genes of interest (COL1A1, COL1A2, COL6A1,
COL6A2 and COL23A1). B. Correlogram of Spearman’s correlation matrix comparing collagen
and TMI signature and collagen genes to KIM-1 mRNA expression levels in human RCC
patients. Correlation co-efficient ranging from +1 to -0.5 were plotted and used to create visual
comparative heat map. Perfect correlations noted as +1 or -1, for both positive and negative
correlations to KIM-1 expression, respectively. Each plot in correlogram represents a gene
correlation to KIM-1, for each patient analyzed (KIPAN (total): n = 1019: KIRC: n = 606, KIRP:
n = 321, KICH: n = 90, N/A: n = 2 – excluded from analysis due to non-matching).

3. 4 KIM-1 expression on RCC cell does not alter their tumorigenic potential
when injected bilaterally into BALB/c mice.
To investigate the role of KIM-1 expression on the growth of RCC tumours, we injected 1 x 106
KIM-1pos and KIM-1neg Renca cells into the flanks of 6-8-week-old female BALB/c mice for 21
days. MatrigelTM incorporation into injection methods influences uniformity and reproducibility
of Renca tumour models by maintaining the integrity of cells after subcutaneous injection (Yu et
al., 2018). Cells were either resuspended in 100L of 1 x PBS alone and/or 1:1 dilution of 1 x
PBS and Corning (GFR) MatrigelTM Membrane, subcutaneously into the right flanks of 6-8week-old female mice, to rule out any effects of MatrigelTM use on tumour development.
Bilateral injection of Renca tumours allowed us to compare tumour growth between KIM-1pos
and KIM-1neg tumours in the same host (i.e., same immune system). I did not observe any
significant differences in tumour volume or mass between KIM-1pos and KIM-1neg tumours both
without MatrigelTM (Fig 4A) or with MatrigelTM (Fig 4B).
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A.

B.

Figure 4. Mass and volumes of KIM-1pos and KIM-1neg Renca tumours grown SQ-Bilat.
A. KIM-1pos and KIM-1neg Renca tumour volume and mass, grown without MatrigelTM for 21
days in 6–8-week-old female mice (n=11/group) (volume: NS, p=0.3080, mass: NS, p=0.3251).
B. KIM-1pos and KIM-1neg Renca tumour volume and mass, grown with MatrigelTM for 21 days
in 6–8-week-old female mice (n=24/group) (volume: NS, p=0.3673, mass: NS, p=0.4629). Data
is represented as mean measurement of tumour size/volume (mm3), and mass (g) ± SEM
(NS=not significant, Unpaired two-tailed t-test).
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3.5 KIM-1 expression in Renca cells does not alter tumorigenic potential when
injected unilaterally into BALB/c mice.
Next, I investigated whether unilateral injection methods of KIM-1pos or KIM-1neg Renca cells
into the flanks of BALB/c mice would change the results observed in the previous experiment. I
argued that if KIM-1 expression in Renca cells had any effect on the anti-tumour immune
response to Renca tumours, unilateral injection of the KIM-1pos and KIM-1neg cells into separate
mice would result in differences between the two groups. Once again, I either suspended the
Renca cells in a 1 x PBS alone or a 1:1 dilution of 1 x PBS with Corning (GFR) MatrigelTM
Membrane. Again, I did not observe any differences between KIM-1pos and KIM-1neg Renca
tumour volume or mass in our unilateral model both without MatrigelTM (Fig 5A) or with
MatrigelTM (Fig 5B). Since I found no differences between SQ-Bilat or SQ-Unilat tumour
volumes and masses, here on in I decided to analyze tumour specimens only with the
incorporation of MatrigelTM for our various models.
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Figure 5. Mass and volumes of KIM-1pos and KIM-1neg Renca tumours grown SQ-Unilat.
A. KIM-1pos and KIM-1neg Renca tumour volume and mass, grown without MatrigelTM for 21
days in 6–8-week-old female mice (KIM-1neg: n=10, KIM-1pos: n=11) (volume: NS, p=0.9071,
mass: NS, p=0.1538). B. KIM-1pos or KIM-1neg Renca tumour volume and mass, grown with
MatrigelTM for 21 days in 6–8-week-old female mice (n=8/group) (volume: NS, p=0.7854, mass:
NS, p=0.3005). Data is represented as mean measurement of tumour size/volume (mm3), and
mass (g) ± SEM (NS=not significant, Unpaired two-tailed t-test).
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3.6 Tumour KIM-1 expression does not influence immune infiltration of
lymphocytes in the subcutaneous Renca model.
To investigate the effect of KIM-1 expression on the immune response against Renca tumours, I
compared the immune infiltrate between KIM-1pos and KIM-1neg Renca tumours grown
subcutaneously within female immune competent BALB/c mice using co-immunofluorescence
staining for CD3+, CD3+CD4+, and CD3+ CD8+ cells. We examined tumours at 21 days postinjection to allow for maximal infiltration of immune cells. There were no significant differences
in tumour infiltrating CD3+, CD4+, or CD8+ immune cells between Renca KIM-1pos (Fig 6A) and
KIM-1neg (Fig 6B) tumours (Fig 6C).

A.
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Figure 6. Co-immunofluorescence staining for CD3+, CD4+ and CD8+ invading lymphocytes in
KIM-1pos and KIM-1neg Renca tumours 21 days after SQ-Bilat injection.
A. KIM-1pos and B. KIM-1neg Renca tumour stained with CD3+ (green) CD4+ (blue) CD8+
(white) conjugated antibodies (n=4/group). C. Quantification of the various types of immune
infiltrates counted within tumours. Designated arrows pointing to cell types [CD3+ (green) CD4+
(blue) CD8+ (white)] on inlet images. All images were taken via widefield microscopy using
Leica Software at 10x and 100x magnification, respectively. Immune infiltrates were enumerated
using Fiji manual cell counter software. Data is represented as mean measurement of number of
immune infiltrates per tissue surface area ± SEM (CD4+. p= 0.218575, NS; CD8+, p= 0.999170,
NS; CD3+, p = 0.859486, NS; CD3+CD8+, p=0.875091, NS. Unpaired two-tailed t-test).
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3.7 KIM-1pos Renca tumours are enveloped in a collagen-rich capsule.
Since I elucidated that various collagen genes are significantly upregulated in RCC patient
tumours, I next examined differences in connective tissues within KIM-1pos and KIM-1neg Renca
tumours at endpoint (21 d) by staining for collagen using Masson's Trichrome stain. KIM-1pos
tumours were found to be surrounded by a significantly thicker collagen dense capsule compared
to the KIM-1neg tumours (Fig 7A-C). Importantly, the collagen dense capsule was found to be
prominent in Renca KIM-1pos regardless of whether the Renca cells were injected bilaterally into
either flank of the same BALB/c mice or unilaterally into independent mice (MatrigelTM) (Fig
8A-C).
A.

C.

B.
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Figure 7. Collagen deposition in KIM-1pos and KIM-1neg Renca tumours injected SQ-Bilat in
female BALB/c (WT) mice.
Micrograph of A. KIM-1pos and B. KIM-1neg Renca tumour stained with Masson’s Trichrome
elucidating the collagen stromal capsule (KIM-1neg: n=7, KIM-1pos: n=4). All images were taken
at 100x magnification using brightfield microscopy and NIS-Elements Nikon software. C. Width
(μm) quantification of collagen tumour capsule from KIM-1neg and KIM-1pos Renca tumours.
Data is represented as mean measurement of tumour capsule width (μm) ± SEM (****,
p<0.0001, Unpaired two-tailed t-test).

A.

C.

B.
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Figure 8. Collagen deposition in KIM-1pos and KIM-1neg Renca tumours grown SQ-Uni in
female BALB/c mice.
Micrograph of A. KIM-1pos and B. KIM-1neg Renca tumours stained with Masson’s Trichrome
elucidating the collagen stromal capsule (KIM-1neg: n=7, KIM-1pos: n=8). All images were taken
using brightfield microscopy and NIS-Elements Nikon software. C. Width (μm) quantification of
collagen tumour capsule from KIM-1neg and KIM-1pos Renca tumours. Data is represented as
mean measurement of tumour capsule width (μm) ± SEM (**, p = 0.0049, Unpaired two-tailed ttest).

3.8 The collagen-dense capsule surrounding KIM-1pos Renca tumours does not
depend on the host adaptive immune system.
To determine whether the differences in collagen dense capsule surrounding the Renca
KIM-1pos tumours was dependent on an intact adaptive immune system of the host, I examined
KIM-1pos and KIM-1neg Renca tumours growth in immune deficient Rag-1-/- mice on the BALB/c
background. Once again, the tumours were collected 21 days post-injection and sections were
stained with Masson’s Trichrome stain. KIM-1pos Renca tumours exhibited significantly thicker
collagen dense capsules in comparison to KIM-1neg Renca tumours (Fig 9A-C).
A.

B.
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Figure 9. Collagen deposition in KIM-1pos and KIM-1neg Renca tumours grown SQ-Bilat in
Rag1 -/- mice.
Micrograph of A. KIM-1pos and B. KIM-1neg Renca tumour stained with Masson’s Trichrome
elucidating the collagen stromal capsule (n=5/group). All images were taken at 100x
magnification using brightfield microscopy and NIS-Elements Nikon software. C. Width (μm)
quantification of collagen tumour capsule from KIM-1pos and KIM-1neg Renca tumours. Data is
represented as mean measurement of tumour capsule width (μm) ± SEM (*, p = 0.0120,
Unpaired two-tailed t-test).

3. 8 KIM-1 expression inhibits Renca tumour growth in an orthotopic model
of RCC.
RCC tumours arise from the proximal tubule of the kidney and can metastasize to distant sites
such as the lung. To test the role of KIM-1 on tumour growth within the kidney and on
metastasis to the lungs, I orthotopically injected KIM-1pos or KIM-1neg Renca cells into the renal
subcapsular space of BALB/c mice. Previous studies have claimed that Renca cells are able to
grow in the kidney and preferentially metastasize to the lungs within 2 weeks of intra-renal
injection (Feldman et al., 2016). Renca cells were injected with MatrigelTM into the subcapsular
region of the left kidney. The volume and weights of the KIM-1pos Renca tumours were
significantly lower than KIM-1neg Renca tumours (Fig 10). Mice injected with KIM-1pos Renca
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cells also had fewer metastatic lung nodules compared to mice injected with KIM-1neg Renca
cells, albeit this was not significant (Fig 13A-C).

Figure 10. Volumes and weights of KIM-1pos and KIM-1neg Renca tumour after orthotopic
injection into BALB/c mice.
Tumour bearing kidney volume and mass respectively, 21 days post orthotopic injections of
KIM-1pos or KIM-1neg Renca cells (n=15/group). Data is represented as mean measurement of
tumour size/volume (mm3), and mass (g) ± SEM (volume, **, p = 0.0024; mass, **, p = 0.0045,
Unpaired two-tailed t-test).

3. 9 KIM-1pos Renca tumours do not produce a collagen rich capsule when
injected orthotopically into BALB/c mice.
To investigate if orthotopic injection of KIM-1pos Renca cells produce tumours with a
collagen rich capsule, both KIM-1pos and KIM-1neg Renca tumours grown orthotopically in
female BALB/c mice were subjected to Masson's Trichrome staining. Analysis of kidney bearing
tumours revealed no measurable differences in capsule size between both KIM-1pos and KIM-1neg
kidney bearing tumours (Fig 11A and B).
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A.

B.

Figure 11. Collagen deposition in KIM-1pos and KIM-1neg Renca tumours grown orthotopically
in BALB/c mice.
Micrograph of A. KIM-1pos and B. KIM-1neg kidney bearing Renca tumours stained with
Masson’s Trichrome elucidating the lack of collagen stromal capsule. All images were taken at
100x magnification using brightfield microscopy and NIS-Elements Nikon software.

3.10 Tumour KIM-1 expression does not influence immune infiltration of
invading lymphocytes in the orthotopic Renca model.
Next, I investigated whether KIM-1 expression on Renca tumours had any effects on
tumour infiltrating T cells in our orthotopic model. KIM-1pos and KIM-1neg tumour-bearing
kidneys were stained for CD3+, CD3+CD4+, and CD3+ CD8+. We examined tumours at 21 days
post-injection to allow for maximal infiltration by immune cells. There were no significant
differences in tumour infiltrating CD3+, CD4+, or CD8+ T cells between Renca KIM-1pos and
KIM-1neg tumours (Fig 12A-C).
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Figure 12. Co-immunofluorescence staining for CD3+, CD4+, and CD8+ invading lymphocytes
in KIM-1pos and KIM-1neg Renca orthotopic tumours from BALB/c mice after 21 days.
Micrographs of A. KIM-1pos and B. KIM-1neg Renca tumour stained for CD3+ (green) CD4+
(blue) CD8+ (white) (KIM-1pos: n=3, KIM-1neg: n = 2). C. Quantification of the various types of
immune infiltrates counted within tumours. Designated arrows pointing to cell types [CD3+
(green) CD4+ (blue) CD8+ (white)] on inlet images. All images were taken via widefield
microscopy using Leica Software at 10x and 100x magnification, respectively. Immune
infiltrates were enumerated using Fiji manual cell counter software.

3. 11 KIM-1 expression does not affect spontaneous metastasis from the
kidneys to lungs in the orthotopic model of RCC.
We next investigated whether KIM-1 expression had any impact on the process of
metastasis from the kidney to the lungs by collecting the lungs at day 21 and examining them for
metastatic nodules using microscopy. Histological examination of the lung tissues revealed no
statistically significant differences in the number of metastatic nodules, as well as no differences
in collagen encapsulation between mice injected orthotopically with KIM-1pos or KIM-1neg Renca
cells (Fig 13A-C).
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Figure 13. Number of metastatic lung nodules in BALB/c mice injected orthotopically with
KIM-1pos or KIM-1neg Renca cells.
Micrographs of H&E-stained sections of lung tissue excised from A. KIM-1pos and B. KIM-1neg
Renca cell treated mice (n=8/group). C. Quantification of metastatic lung nodules formed within
both KIM-1pos and KIM-1neg Renca cell treated mice. Nodules were enumerated by manually
counting visualized metastases. Metastases are indicated using arrows. All images were taken
using brightfield microscopy and NIS-Elements Nikon software. Data is represented as mean
measurement of number of metastatic nodules per tissue surface area ± SEM (NS, p = 0.2073,
Unpaired two-tailed t-test).
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3.12 KIM-1 expression in Renca cells promotes transcription of genes involved
in the formation and interaction with extracellular matrix.
To understand how KIM-1 expression promotes the formation of collagen rich capsules by
Renca tumours, I analyzed our previously generated RNA sequencing data from both KIM-1pos
and KIM-1neg Renca cells (Lee and Gunaratnam, 2019). The most significant gene enrichment
that was upregulated within the Renca KIM-1pos cells was in genes involved in Extracellular
Matrix Interaction (p < 0.05, fold change 1.96) (Fig 14A and B). This enrichment contained
genes involved in the interaction and deposition of extracellular matrix (ECM). Moreover, the
most significantly upregulated collagen genes within KIM-1pos Renca cells was COL6A1 and
COL6A2 (Fig 14C).
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Figure 14. Illumina RNA-Sequencing transcriptomic analysis of enriched Extracellular Matrix
Genes between KIM-1pos and KIM-1neg Renca cell lines.
A. Heat map generated from RNA Sequencing data of KIM-1pos and KIM-1neg Renca cell lines
(n=3/group), displaying differential gene enrichment analysis of extracellular matrix (ECM)
genes (p>/=0.05). Genes with increased numbers of transcripts are marked as red, while
decreased are marked as green. B. List of ECM genes that have significant increased expression
in KIM-1pos Renca cells, in comparison to KIM-1neg Renca cells. C. Collagen 6 A 1 and Collagen
6 A 2 mRNA expression level within both KIM-1pos (red) and KIM-1neg (blue) Renca cells.

Table 1. Mouse Oligonucleotide PCR primer sequences

Gene
mKIM-1
(murine)
GAPDH
(murine)

Primer Sequence (5’
3’)
Forward Sequence
Reverse Sequence
TCAGCATCTCTAAGCGTGGT
ATGTTGTCTTCAGCTCGGGA
AGGTCGGTGTGAACGGATTTG

TGTAGACCATGTAGTTGAGGTCA
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Chapter 4
4. Discussion
4.1 Major Findings
4.1.1 KIM-1 (Havcr1) mRNA is expressed at all stages of RCC and increases
overall patient survival
Multiple studies have identified KIM-1 as a urine or blood biomarker for the early
detection of RCC (Scelo et al., 2018). This was made possible through sensitive detection of
shed or soluble KIM-1 (sKIM-1) in the blood plasma and urine (Scelo et al., 2018) of RCC
patients. Our laboratory previously showed that cell-surface KIM-1 is shed by ADAM17 or
TACE in RCC cells (Gandhi et al., 2014). Using the TCGA KIPAN database, specifically
analyzing KIRC (Kidney Clear Cell Carcinoma) and KIRP (Kidney Papillary Carcinoma) patient
databases, I was able to show that increased KIM-1 mRNA is highly upregulated in human RCC
patients (Fig 1). KIM-1 expression was found to be significantly increased as early as stage I
disease, with persistent expression through stages I-IV. Given that KIM-1 is only upregulated
during acute kidney injury (AKI) (Han et al., 2005), and the early detection of KIM-1 in the
blood of RCC patients (Scelo et al., 2018), these data confirm that KIM-1 is likely upregulated in
early RCC lesions (Han et al., 2002). The reason for this upregulation is unclear, but it is not due
to VHL-loss of function (unpublished observations). In addition, higher KIM-1 expression was
associated with significantly increased overall survival rates in KIRC (ccRCC) patients, yet not
KIRP (papillary RCC) patients (Fig 1C, D and E). These data are in contradiction to findings
reported by Scelo and team (Scelo et al., 2018), that high plasma KIM-1 concentrations were
associated with poorer survival. Our study, however, examined endogenous tumour KIM-1and
not soluble (shed) KIM-1.
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Many groups, including Dr. Gunaratnam’s, have shown that during AKI, KIM-1 converts
proximal tubular epithelial cells (PTECs) into semiprofessional phagocytes for clearance of
apoptotic and necrotic cells of (Arai et al., 2016). KIM-1 recognizes and binds to
phosphatidylserine (PtdSer) – a phospholipid abundantly expressed on early necrotic and
apoptotic cells – via the metal ion-dependent ligand binding site within its IgV domain (Nagata
et al., 2016). The clearance of dying cells leads to curtailment of inflammation and promotes
tissue repair. The function of KIM-1 in RCC may be linked to its reparative role in the healthy
kidney during acute injury, where an increase in KIM-1 expression reduces the amount of
apoptotic or early necrotic cells formed in tumours, thereby significantly reducing tumour burden
and promoting cell regeneration and repair (O. Z. Ismail et al., 2016). This in turn could explain
why patients with higher levels of KIM-1 expression, exhibit more favorable outcomes.

4.1.2 ECM signatures are upregulated in human RCC
Previous studies have underscored the importance of tumour stroma and ECM components in
tumour progression and metastasis (Yuzhalin et al., 2018). RCC is known to upregulate adhesion
molecules (Chen et al., 2016), moreover, several collagen genes exhibiting increased mRNA
expression have been found in human RCC tumours and linked to tumour grade (Best et al.,
2019). Collagen genes such as Collagen 1 (COL1) (Majo et al., 2020), Collagen 6 (COL6) (Wan
et al., 2015), and Collagen 23A1 (COL23A1) (Xu et al., 2017) have been shown to be
upregulated in RCC tumours. Collagen in cancer has been found to be both beneficial and
detrimental to patients in terms of tumour progression (Fang et al., 2014), although the
mechanistic role of collagen in RCC is not well understood. Furthermore, chronic KIM-1
expression after AKI has been linked to kidney fibrosis in vivo (Humphreys et al., 2013). Our
analysis of the TCGA using KIRC and KIRP patient cohorts revealed that various collagen genes
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(i.e. COL1A1, COL1A2, COL6A1, COL6A2, and COL23A1) were all significantly upregulated in
RCC tumour tissues vs adjacent normal tissues (Fig 2). A recent study found that Col6a1
promotes metastasis and a poorer prognosis in pancreatic cancer patients (Owusu-Ansah et al.,
2019). Another study found Col23A1 is upregulated in RCC, and contributes to tumour
progression (Xu et al., 2017). On the other hand, down-regulation of Col1A2 by methylation
was found in both bladder (Mori et al., 2009), and melanoma cancer (Bonazzi et al., 2011). The
role of these various collagen genes across multiple types of cancer remains controversial. When
correlating KIM-1 expression to the TMI signature gene list (Lim et al., 2019), along with
previous collagen genes of interest (COL1A1, COL1A2, COL6A1, COL6A2, and COL23A1), I
found no clear correlation trends between these collagen signatures and KIM-1 expression in
RCC patients (Fig 3). Although, when comparing KIM-1 expression to COL1A2, COL6A1,
COL6A2, and COL23A1 - these were found to positively correlate to KIM-1 expression in RCC.
Many of the genes within the TMI signature (Lim et al., 2019) had either a significant positive or
negative correlation to tumour KIM-1 mRNA – although further investigation behind the specific
genes must be completed before additional conclusions can be made. Previous research has
shown that during AKI, KIM-1 expression is beneficial in early acute stages of injury but chronic
expression of KIM-1 promotes renal fibrosis (Humphreys et al., 2013). Cell types implicated in
the process of fibrosis are fibroblasts and myofibroblasts that aid in tissue remodeling and the
secretion of extracellular matrix components such as collagen (Wynn, 2008). The positive
correlation of collagen genes in KIM-1 expressing Renca cells may be a protective mechanism
by the kidney. It may be possible that KIM-1 expression in renal malignancies causes similar
effects. This would suggest that chronic KIM-1 expression leading to fibrosis, may be a
dominant phenotype of KIM-1 not only in kidney injury, but possibly in RCC. However, the
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exact interaction – if present – between KIM-1 and COL1A2, COL6A1, COL6A2, and COL23A1
needs to be confirmed through more mechanistic studies.

4.1.3 KIM-1 does not alter tumour growth in an immune competent
subcutaneous Renca model
Multiple studies have identified the subcutaneous model as a stable murine model to study RCC
tumour biology (Sobczuk et al., 2020). Using the bilateral and unilateral subcutaneous models, I
compared the growth of KIM-1pos and KIM-1neg Renca tumours in immune competent mice. The
bilateral model is an ideal model to use as it minimizes the genetic heterogeneity between
individual mice that could cause variations in response to the same treatment. Bilateral models
are better suited to studying the effect of tumours on the host immune system (e.g. immune
check-point blockade) (Zemek et al., 2020). I found that KIM-1 had no effect on tumour growth
regardless of whether we used the bilateral or unilateral approach (Fig 4 and 5). Previous studies
have found that Renca tumour growth in vivo had inconsistent tumour growth kinetics in the
absence of MatrigelTM (Yu et al., 2018). Following this study, I revised my protocol to
CDTRresuspend our Renca cells in growth factor reduced MatrigelTM prior to both bilateral and
unilateral subcutaneous injection. My studies produced consistent tumour sizes and masses with
smaller standard deviations. Therefore, I am confident of my findings showing that KIM-1
expression does not alter the tumour size or mass produced by Renca cells implanted
subcutaneously into immune competent mice.
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4.1.4 KIM-1 expression promotes the formation of a collagen dense capsule
around Renca tumours injected subcutaneously into both immune competent
and immune deficient mice
Dysregulated collagen production has been linked to a more malignant phenotype in various
cancers (Seager et al., 2017). On the other hand, many benign tumours are known to be
surrounded by a capsule consisting of connective tissue. My findings suggest that KIM-1
expression promotes transcription of various collagen genes in human RCC tumours and
formation of a collagen-rich capsule surrounding the Renca tumours. Interestingly, I observed
the formation of the capsule around KIM-1pos Renca tumours only when injected subcutaneously
but not orthotopically (Fig 7, 8 9, and 11). The use of MatrigelTM did not affect these results.
Some studies have suggested that the collagen rich tumour capsule directly interacts with the
host immune system, and thus, the ensuing interaction strongly impacts tumour progression
(Seager et al., 2017). Given that the tumour capsule was present on KIM-1pos Renca tumours
grown in wild type BALB/c and RAG1-/- BALB/c mice, my data suggests that the formation of
the capsule does not depend on the interaction of tumour cells and the adaptive immune system,
yet is dependent on the site of injection (subcutaneous vs orthotopic). Specifically, we can
assume that the collagen capsule is localized to the tumour stroma due to the interaction between
tumour-associated KIM-1 and the surrounding cells of the subcutaneous microenvironment.
Given that there were no differences in volume or mass between the subcutaneous KIM-1pos and
KIM-1neg Renca tumours regardless of host immune status (WT BALB/c or Rag1-/- BALB/c
mice), it could be argued that the capsule does not alter the T- or B cells responses against the
tumours, in opposition to previous studies (Salmon et al., 2012).
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4.1.5 KIM-1 expression does not alter frequency or distribution of invading
lymphocytes in both subcutaneous and orthotopic Renca models
The tumour microenvironment plays a key role in anti-tumour immunity (Applegate, Balch and
Pellis, 1990). Intra- and extra-tumoral cell signaling, tumour and cell metabolism, and
oxygenation are all factors that influence tumour progression and metastasis - can be determined
by the surrounding tumour microenvironment (Henke, Nandigama and Ergün, 2020). Tumour
microenvironment components can differ significantly between tumour types, but the main
components are invading or surrounding immune cells, the vasculature, stromal cells and the
tumour associated ECM (Anderson and Simon, 2020). In most cases, the tumour cells seem to
orchestrate the surrounding cells to promote a microenvironment favorable for growth and/or
metastasis (Walker, Mojares and Del Río Hernández, 2018). It is well known that tumour
associated ECM (including collagen) is able to inhibit the invasion of immune cells into the
tumour parenchyma and/or alter the phenotype of the invading immune cells to promote cancer
progression (Maller et al., 2020). Also, depending on the density of tumour associated collagen,
the ECM can inhibit the positioning and migration of T cells, resulting in possible T cell
exclusion from the tumour periphery (Kuczek et al., 2019). Increased tumoral collagen has also
been found to exhaust CD8+ T cells through direct contact with T cell markers, LAIR1 (Peng et
al., 2020). This phenomenon has been observed in many cancers such as triple-negative breast
cancer, pancreatic cancers (Kuczek et al., 2019) and lung cancer (Salmon et al., 2012).
Organization and location of tumour associated ECM structures are commonly positioned around
vasculature structures or the stromal interface. Specifically, research has shown that both
perivascular and loose organized structures of the ECM in particular are where most of the intratumoral T cell migration occurs (Salmon et al., 2012). I was able to elucidate that my KIM-1pos
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Renca tumours develop significantly thicker collagen dense stromal capsules. Yet, I observed no
significant differences in the distribution or frequencies of invading lymphocytes within
subcutaneous KIM-1pos or KIM-1neg Renca tumours (Fig 6). CD4+ and CD8+ T cells were chosen
for analysis due to the compelling research that: 1) T cells are fundamental to anti-tumour
immunity; 2) known exclusion or inhibitory mechanisms via collagen deposition targets both T
cell subsets.

We have no concrete conclusions about the distribution or frequency of invading lymphocytes
within KIM-1pos and KIM-1neg Renca tumours grown orthotopically (Fig 12). Due to the small
sample size of my KIM-1neg group, additional experiments will be required to confirm whether or
not there are any real differences. Further characterization of the immune infiltrate and
evaluation of the effector function of invading lymphocytes in KIM-1pos vs. KIM-1neg Renca
tumours, may help elucidate the mechanism responsible for inhibiting tumour growth in our
orthotopic model.

4.1.6 KIM-1 expression inhibits tumour growth in an orthotopic Renca model
Subcutaneous tumour models are widely used for in vivo cancer studies and allows for growth of
the tumour below the skin to become a highly vascularized area. This allows for rapid tumour
growth that is easily monitorable using calipers, permitting a rapid assessment of growth kinetics
overtime (Zhang et al., 2019). There are several limitations to the subcutaneous tumour model in
comparison to other experimental cancer mouse models. Subcutaneous tumour models allow for
the simple monitoring of biological staging yet are is not feasible for studying metastasis (Zhang
et al., 2019) – as it is not often observed in subcutaneous models (Gomez-Cuadrado et al., 2017).
Researchers have brought to light that the development of tumours in subcutaneous tissue may
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not reflect the development of human cancers in native tissues (Zhang et al., 2019). Therefore,
orthotopic mouse models are regarded as a more clinically relevant model for the study of human
cancers including progression, metastasis and therapeutic intervention. Orthotopic models have
been shown to better correspond to human cancer development in terms of histology, tumour
vasculature, response to therapies/treatments, and of course the metastatic cascade to nearby and
distant organs (Khanna and Hunter, 2005). A recent study evaluating BB3r-targeted therapy in
both subcutaneous vs orthotopic mouse models of prostate cancer, found that orthotopic models
had overall higher tumour uptake, increased vascular perfusion, and lower burden of hypoxia.
Overall findings from this study concluded that the tumour microenvironmental differences
between subcutaneous and orthotopic models differs greatly (Zhang et al., 2019). Another study
recently compared the interactome profiles of gastric cancer – OE19 adenocarcinoma - using
both subcutaneous and orthotopic xenograft models. Pathway analysis using RNA sequencing
revealed various significantly enhanced pathways within orthotopic models in comparison to
subcutaneous models. More vascular invasion were found within orthotopic models - observing
increased interactions between cancer and stromal cells – with orthotopic models thought to have
higher interplay with the surrounding microenvironment (Nakano et al., 2018). Prior to our
research, the discrepancies between subcutaneous vs orthotopic models in RCC was unknown.
Overall, I am the first to uncover the major differences between subcutaneous and orthotopic
mouse Renca tumour models and how they dictate the interaction between cancer cells and
surrounding stromal cells. My results found that KIM-1pos Renca cells create significantly
smaller primary tumours in - comparison to KIM-1neg Renca cells - when injected orthotopically
into the subcapsular space of the kidney, but not subcutaneously, in immune competent mice
(Fig 10). My results support previous evidence revealing KIM-1 as a potential protective player
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in RCC (Lee and Gunaratnam, 2019), as patients with higher levels of KIM-1 expression resulted
in an increased overall survival rate (Fig 1C). However, my findings also differ from that of
(Cuadros et al., 2013), who proposed that KIM-1 promotes tumour progression. In contrast to
these studies, my findings suggest KIM-1 does not promote tumour progression, and in fact,
inhibits tumour growth in my orthotopic studies.
One study investigated the differences in membrane bound tissue KIM-1 as well as soluble
cleaved KIM-1, in regard to their differential effects on RCC progression. Microvascular
invasion – the invasion of cancer cells into the endothelium of blood vessels – was correlated
with increased tissue KIM-1 expression in clear cell RCC (ccRCC) tumours. This study also
found that increased levels of soluble KIM-1 detected in the urine correlated with increased
TNM staging and overall exacerbated disease progression (Mijuskovic et al., 2018). Another
study stated that when analyzing RCC patient plasma, higher concentrations of soluble KIM-1
were associated with poorer survival rates (Scelo et al., 2018). On the other hand, the
Gunaratnam laboratory has shown that KIM-1 expression on TECs is able to inhibit Gα12,
subsequently inhibiting a small GTPase RhoA, which is found to increase metastatic progression
of cancers (Z. O. Ismail et al., 2016). Although the mechanistic correlation between KIM-1 and
Gα12 expression in RCC in vitro/in vivo work was not further investigated. Despite these
findings, the clear role of KIM-1 expression in the pathogenesis and progression of RCC remains
not well understood. The discrepancy between my study and those discussed above may be
explained by my studies involving multiple in vivo systems (subcutaneous vs orthotopic), and
correlation of both in vitro and in vivo experimental data with TCGA patient database findings.
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4.1.7 KIM-1 does not promote collagen capsule formation in an orthotopic
Renca model
As mentioned above, previous studies have shown that orthotopic tumour models better mimic
the natural biology of tumour progression (Nakano et al., 2018). Surprisingly, my data showed
no significant differences between KIM-1pos and KIM-1neg collagen capsules in our orthotopic
model (Fig 11), yet in our subcutaneous model, KIM-1pos Renca tumours bared significantly
thicker collagen dense capsules in both immune competent and deficient mice. This discrepancy
may be explained by differences in the (tumour) surrounding cells (skin vs. kidney) which the
Renca cells recruit to form the microenvironment. Conceivably, the skin may be a more
permissive environment for the formation of a collagen rich matrix (Cox and Erler, 2011). One
study found that the adipose tissue of rats located within the subcutaneous space, strongly varied
from visceral adipose tissue. This study observed subcutaneous adipose gene clusters strongly
relating to ECM related genes involving collagen, cell adhesion, and proteases. Expression
profiles revealed major fibril-forming collagen genes that were upregulated were Collagen I,
Collagen III, Collagen V, and Collagen VI, along with the more common ECM related genes
such as Lama, Fibronectin 1, and Collagen IV (Mori et al., 2014). Although this study was
performed in rats, previous research on adipose tissue has suggested that both mice and rats are
comparable to one another (National Human Genome Research Institute, 2004). Another study
found that when comparing ECM of subcutaneous tumours and in vitro tumour spheroids (a
three-dimensional cell culture model), the subcutaneous tumours had an increased collagen
content (De L Davies et al., 2002) likely due to the proximity to cells within the adjacent
connective and dermal adipose tissues (Wojciechowicz et al., 2013). These previous findings
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may give reason as to why we observed a significantly thicker collagen capsule formation in
KIM-1pos Renca tumours within our subcutaneous, but not orthotopic model.

4.1.8 KIM-1 does affect spontaneous metastasis of Renca cells to the lungs in
an orthotopic model
Late stage RCC (III-IV) involves tumour growth into the renal vein, inferior vena cava, or to
regional lymph nodes, each of which must pass the Gerota’s fascia – the fibrous envelope
encapsulating the kidney. Common sites of metastasis in RCC include the lungs, adrenal glands,
and bones – whilst the lungs being the most common site of metastasis, found in up to 50%-60%
of autopsies (Reznek, 2004). Orthotopic injection of Renca cells are widely used as a model to
study the metastatic cascade of RCC (Hillman, Droz and Haas, 1994; Gomez-Cuadrado et al.,
2017). Although our orthotopic experiments revealed that the KIM-1pos Renca tumours were
considerably smaller than the KIM-1neg Renca tumours, the small sample size precluded
determining whether there were significant differences in the metastatic potential to the lungs
between the KIM-1pos or KIM-1neg Renca cells (Fig 13). My data showed significantly fewer
metastatic nodules compared to other studies employing Renca cells (Feldman et al., 2016)
where metastatic nodules compromised ~70% of lung tissue, whereas in my study both KIM-1pos
and KIM-1neg Renca treated mice had only ~15 metastatic nodules observed per mouse.
Secondary metastatic nodules also presented no differences in collagen encapsulation between
groups. There are multiple potential explanations as to why I observed less metastasis in my
experiments. I followed the protocol from Feldman Ret al., injecting 2 x 105 KIM-1pos or KIM1neg Renca cells into the subcapsular space of the left kidney. This study used an endpoint for the
assessment of metastases at 14 days post-injection and this resulted in sufficient primary tumour
growth as well as secondary metastases compromising up to ~70% of resected lung tissue
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(Feldman et al., 2016). Another study by Murphy et al., injected Renca cells directly into the
kidney – intrarenal implantation – to study metastatic RCC for the assessment of preclinical
therapies (Murphy et al., 2017). At 23 days after injection of Renca cells into the renal
cortex/medulla, using BLI to assess tumour burden, this study observed significantly more
metastasis than I did with subcapsular injection. Potential explanations for the low numbers of
metastatic nodules in my model could be: 1) Subcapsular vs. intra-renal injection of Renca cells;
2) improper injection and leakage of cells outside the kidney; 3) reduced malignancy of our
Renca cell lines upon transduction with Lentivirus. The use of luciferase expressing Renca cells
may allow for more sensitive detection of metastatic foci when using real -time bioluminescent
imaging (BLI).

4.1.9 KIM-1 expression increases transcription of ECM related genes in
Renca cells
My data from the subcutaneous model of RCC revealed that KIM-1pos Renca tumours obtain a
significantly thicker collagen dense stromal capsule in comparison to KIM-1neg Renca tumours,
independent of adaptive immunity. Surprisingly, my orthotopic model of RCC revealed no
significant differences in collagen stromal capsule formation between my tumour groups. In
efforts to elucidate how KIM-1 expression may alter mechanistic pathways allowing for ECM
production in our subcutaneous model, I interrogated the transcriptomic profile of KIM-1pos and
KIM-1neg Renca cells using RNA sequencing and bioinformatic approaches. My data did not
show many significant differences between our cell lines in terms of pathway analyses, yet we
did detect a significant gene enrichment of genes involved in Extracellular Matrix Interactions
(Fig 14). Many of the genes involved in this enrichment, are involved in extracellular matrix
synthesis and deposition. These data suggests that KIM-1 expression in Renca cells may activate
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a transcription factor which regulates multiple extracellular matrix related genes. I believe these
findings correlate to the clinically relevant findings from TCGA between KIM-1 and collagen.
Interestingly, two significantly upregulated genes that were found in the RNA Sequencing of the
Renca cell lines – COL6A1, COL6A2 – are also found in my TCGA data where these collagens
are significantly upregulated in RCC patient and positively correlate with KIM-1 expression.
These findings further validate our KIM-1 overexpression Renca model, revealing the
similarities between our Renca cell lines and RCC patient transcriptomic profiles.

4. 2 Limitations
4.2.1 Subcutaneous Mouse Model
Although subcutaneous models are widely used in oncological research, there are major
drawbacks of this method. Initially I had difficulties in trying to overcome the variability in
tumour volume and weight differences between our KIM-1pos and KIM-1neg groups. As stated
previously, there are many drawbacks of the model, most of which surround the
microenvironment, and clinical relevance. Studies have found that subcutaneous models
although non-invasive, the microenvironment implantation causes the tumour to behave as a
benign tumour rather than malignant tumour, owing to the reduced propensity to form metastases
(Sordat, 2017). One study found significant inconsistencies in tumour formation due to the vast
variations in angiogenesis and tumour vasculature within the subcutaneous pocket where
injections occur (Lwin, Hoffman and Bouvet, 2018). These studies could explain why we had
difficulties obtaining consistent results with our subcutaneous model. Another study investigating various tumour immune profiles of murine syngeneic tumour models - found that
Renca cells were the only cell line within the study that needed to be injected with a growth
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factor reduced basement membrane MatrigelTM, in order to facilitate consistent growth patterns
(Yu et al., 2018). Following this protocol, I repeated my subcutaneous injections of 1 x 106 KIM1pos and KIM-1neg Renca cells this time in a 1:1 dilution of 1x PBS and growth factor reduced
MatrigelTM. With this addition to my subcutaneous injection model, I was able to find data with
tighter standard deviations in my tumour volumes and masses in both KIM-1pos and KIM-1neg
tumour results. Although there was visibly less variability, incorporation of MatrigelTM did not
cause uniformity in shape, resulting in abnormally shaped subcutaneous tumour growth still
remaining an issue. These facts, coupled with my results, underscore the limitations of this
model that are likely related to the microenvironment of the murine subcutaneous tissue.

4.2.2 Orthotopic Experimental Model
Although extremely useful and clinically relevant given the clinical cascade of human RCC, the
orthotopic kidney tumour model is widely dependent on technique (Bibby, 2004). Subcapsular
injections into the kidney are extremely difficult and can easily cause high variability between
injections. A major drawback of orthotopic implantation is the high likelihood of leakage of the
inoculate outside the kidney (Sasaki et al., 2015). Although my surgeries were performed by an
experienced veterinary surgeon and implemented with the use of growth factor reduced
MatrigelTM in order to minimize leaking, this process can still occur late after surgery, and in
some cases are unavoidable. Overall, the orthotopic model remains the most clinically relevant
one despite its technical limitations.

4.2.3 Renca Cell Line
Renca cells are perhaps the most commonly used murine cell lines for in vivo RCC studies. They
are naturally derived from a spontaneous renal adenocarcinoma that arose in a BALB/c mouse,
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making the cell line syngeneic when injected into BALB/c mice. Renca cell lines are known to
not fully reflect the genetics of human RCC, although they importantly possess the VHL (Von
Lippen Lindau) deletion – causing epithelial mesenchymal transition (EMT) and HIF-1 α
stabilization – which accurately represent the biology of human RCC tumours (Wolf, Kimryn
Rathmell and Beckermann, 2020). Despite the overall concrete research that supports the use of
Renca cell lines, I experienced several problems with our subcutaneous models (as stated above)
that could be due to our cell line of choice. Yu et al. studied the tumour immune profiles of
Renca tumours in different syngeneic mouse models and found Renca cells to be highly
immunogenic - able to elicit an adaptive immune response (Yu et al., 2018). Renca tumours are
known to be highly infiltrated by immune cells from both the myeloid and lymphoid lineages
(Wolf, Kimryn Rathmell and Beckermann, 2020). Interestingly, they found that the tumour
immune profile depended on the size of the tumours in vivo. Through RNA sequencing, they
found that smaller tumours (~100mm3) had more immune cell infiltrates (including T cells,
macrophages, and NK Cells), while larger tumours (~500mm3 – 2000mm3) contained more
myeloid derived suppressor cells (MDSC) expressing NOS2/iNOS, and VEGFA. These
transcriptomic changes have an impact on immunosuppression, decreased T cell numbers, and
tumour vasculature. The researchers also stated that Renca cells had to be injected with growth
factor reduced MatrigelTM to obtain consistent and uniform tumours. Taken together with my
data, this suggests that tumour size may be predictive of their immune profiles. Yet, this can pose
great difficulty when finding variability in volumes and weights within tumour groups.
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4.3 Future Directions and Significance
4.3.1 Significance
Overall, our findings are somewhat contradictory to previous reports regarding the role of KIM-1
in RCC. Although, preceding research has evidence to support both theories where KIM-1 can
either be playing a protective role to patients or a harmful role by contribution to tumorigenicity.
Some studies suggest that KIM-1 has oncogenic potential and is able to increase the invasiveness
and progression of RCC tumours (Cuadros et al., 2013). However, clinical data from TCGA
database demonstrates that higher levels KIM-1 (Havcr1) mRNA in RCC patients is associated
with greater overall patient survival (Fig 1C). Many in vivo studies investigating the
pathophysiology of RCC used the subcutaneous murine model, due to ease of measuring the
tumours and simplicity. The orthotopic model of RCC is a more clinically relevant model that
mimics the natural environment (kidneys) of the tumours and their propensity to metastasize to
the lungs. We have shown variance between Renca tumour phenotypes with respect to both
growth kinetics and histological differences in our subcutaneous vs. orthotopic models,
respectively. Despite previous research suggesting that orthotopic models allow for a greater
cancer-stromal interaction (Nakano et al., 2018), my data suggests that the microenvironmental
niche of subcutaneous injections allow for an increased production of collagen rich matrix.
Furthermore, my research demonstrates that increased KIM-1 expression positively correlates
with increased COL6A1 and COL6A2 mRNA expression in both clinical human RCC (TCGA)
data, and our Renca murine cell line. In contradiction of the prevailing view that KIM-1
promotes a more malignant phenotype of RCC, we have showed that KIM-1 expression inhibits
orthotopic tumour growth in immune competent mice. This thesis work highlights the
importance of the tumour model (subcutaneous vs orthotopic) in studying RCC and KIM-1.
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Clinical TCGA data coupled with our data also indicates KIM-1 can possibly inhibit primary
tumour growth within pre-clinical murine models of RCC.

4.3.2 Future Directions
The next phase of this project will focus on optimizing my pre-clinical orthotopic model. Results
from my orthotopic - renal subcapsular RCC model – found significantly fewer lung metastatic
nodules than expected within both KIM-1pos and KIM-1neg Renca cell injected mice. Optimizing
this protocol will allow the proper analyses of whether KIM-1 is able to inhibit the process of
spontaneous metastasis to the lungs in a clinically relevant model of RCC. Next, by subjecting
KIM-1pos and KIM-1neg orthotopic Renca tumours to RNA sequencing, an analysis of identified
genetic alterations could then be linked to KIM-1’s ability to inhibit primary tumour growth. My
previous RNA sequencing showed that KIM-1pos Renca cells have significantly upregulated
enriched genes involved in ECM receptor interaction. This cellular phenotype directly correlated
to KIM-1pos subcutaneous Renca tumours obtaining significantly thicker collagen dense stromal
capsules independent of adaptive immunity. RNA sequencing on KIM-1pos and KIM-1neg
orthotopic Renca tumours, will also help to elucidate any genetic drivers that could be altering
the TME, allowing for the phenotypic differences that I have observed in vivo. Lastly, in my
orthotopic Renca tumour models, I have been able to observe a trending towards significance in
the frequency of CD3+ immune cells – where KIM-1pos contains more in comparison to KIM-1neg
Renca tumours. Although I analyzed the frequency and distribution of CD3+, CD3+CD4+, and
CD3+CD8+ immune cells, I did not evaluate their effector function. Analysis of orthotopic Renca
tumours using flow cytometry to investigate the presence of immunomodulatory cytokines such
as IFNγ and IL-2, could give rise to the functionality of the immune cells present. This analysis
may also elucidate the reasoning behind the significantly reduced size of orthotopic KIM-1pos

80
Renca tumours. These findings can also be elucidated by performing co-immunofluorescence
staining for more specific immune markers such as T-cell exhaustion markers such CD44 or
LY6C, to evaluate the activator state of T lymphocytes present.

Once the orthotopic Renca model is optimized, it will be possible to test the effect of an agonist
anti-KIM-1 antibody (RMT1-10) on the growth, dissemination and development of primary
tumours and metastatic nodules within the orthotopic model (Ichimura, Brooks and Bonventre,
2012). This may determine whether KIM-1’s seemingly inhibitory effect on primary and
secondary tumour growth can be enhanced with RMT1-10 delivery. When treating RMT1-10,
we would expect to see stimulation of KIM-1 which may enhance its anti-tumour growth effects
in RCC cells previously observed by our group (Lee et al., 2021).

4.4 Conclusion
My research has revealed novel insights into the role of KIM-1 in RCC. Moreover, it has
highlighted the significant differences between subcutaneous and orthotopic models used for preclinical oncological studies. The expression of KIM-1 in RCC tumours was associated with
improved overall patient survival based on interrogation of the TCGA database. My pre-clinical
orthotopic model suggests that KIM-1 may play a protective role in RCC. KIM-1 expression in
RCC tumours positively correlated with transcripts for several collagen genes in human RCC
patients. I observed significant discrepancies involving tumour progression and histological
phenotypes between the subcutaneous and orthotopic murine RCC models. More research is
required to fully discern the role of KIM-1 expression in RCC tumour progression, as KIM-1
may serve as a potential therapeutic target.
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Appendices
Appendix 1. Confirmation of KIM-1 expression (KIM-1pos) and absence of KIM-1 expression
(KIM-1neg) through total cell protein lysate, mRNA expression, and cell surface expression of
KIM-1pos and KIM-1neg Renca cell lines.

A.

KIM-1neg KIM-1pos
KIM-1
GAPDH

B.

C.

Supplementary Figure 1. Renca RCC cell line protein, mRNA and surface level expression of
KIM-1, respectively.
Renca cells were transduced using a lentivirus carrying a vector encoding for murine KIM-1
cDNA (KIM-1pos) or empty vector (KIM-1neg). A, Western blot to detect murine KIM-1 in KIM1pos and KIM-1neg Renca cells. B, Relative mRNA expression of KIM-1 (Havcr1) mRNA in
KIM-1pos and KIM-1neg Renca cell lines normalized for expression of housekeeping gene
GAPDH. C, KIM-1pos and KIM-1neg Renca cell line analysis of KIM-1 surface level expression
by flow cytometry using anti-KIM-1 antibody.
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Appendix 2. Periodate Lysine Paraformaldehyde Solution Protocol
Materials for PLP Solution:
•

0.1M Sodium Phosphate Buffer (Dibasic)
●

•

14.18 g Na2HPO4 (Dibasic Sodium Phosphate) + 1L ddH2O

0.1M Sodium Phosphate Buffer (Monobasic Sodium Phosphate)
●

13.8g NaH2PO4 (Monobasic) + 1L ddH2O

•

0.1M Phosphate Buffer (PB) – (stored RT) = 3:1 Dibasic buffer to Monobasic buffer

•

L-Lysine

•

Paraformaldehyde (PFA)

•

Sodium M-Periodate

•

Sucrose (10%, 20%, 30%) Dissolved in 0.1M Sodium Phosphate Buffer

Freezing Tissue:
●

Dry Ice (store in Styrofoam box)

●

Ethanol (put within dry ice)

●

Isopentane (put in metal bin overtop of dry ice)

●

Optimal Cutting Temperature Compound (OCT)

●

Histology Tissue Cassettes

●

Cling Wrap and Tin Foil
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